[
    {
        "pmid": "40819081",
        "title": "Roles of inflammatory cytokines in the pathogenesis of hepatitis B virus-related acute-on-chronic liver failure and CAR-T therapy.",
        "abstract": "investigate association inflammatory cytokine liver function index hepatitis B virusrelated acuteonchronic liver failure HBVACLF patient chimeric antigen receptor CAR therapy recipients aim identifying prognostic biomarkers elucidating pathophysiological role inflammatory cytokine HBVACLF retrospective cohort study analyzed clinical data three groups 68 patient confirmed HBVACLF 30 patient preHBVACLF 372 hematologic malignancy patient receiving CART therapy preserved liver function First Affiliated Hospital Soochow University Serum interleukin IL10 level demonstrated progressive increase across group healthy controls 015 010218 pgmL preHBVACLF 380 2381183 pgmL HBVACLF 595 3901475 pgmL p  0001 Patients clinical improvement exhibited significantly lower IL10 concentration higher IL6IL10 ratio compared disease progression p  005 Notably IL6 level remained stable across clinical stages HBVACLF patient without secondary infection showing lower IL6 level preHBVACLF patient p  005 Following CART therapy hematologic patient displayed significantly elevated IL6 levels accompanied increase AST INR prolongation whereas TBIL ALT remained stable p  005 Consistent HBVACLF observations improved CART recipient demonstrated significantly lower IL6IL10 ratio progression patient p  005 IL10 exhibit stagedependent dynamic HBVACLF pathogenesis progression closely mirroring hepatic functional deterioration IL6IL10 ratio serf prognostic biomarker HBVACLF CART therapyrelated liver injury lower ratio indicating better clinical outcomes applicable",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819081/",
        "source_type": "Global"
    },
    {
        "pmid": "40819053",
        "title": "Sterile syringe availability in Georgia pharmacies remained rare, despite policy change permitting sales.",
        "abstract": "Numerous states including Georgia April 2019 advanced policy designed increase availability sterile syrinx pharmacy people inject drug PWID however extent pharmacy willing sell syrinx PWID unclear examine sterile syrinx sale practice Georgia pharmacy PWID following recent policy change pharmacists cited reason practices conducted telephone survey October 2020 May 2021 one pharmacist staff manager per pharmacy sample Georgia retail pharmacy stratified urbanicity 15question survey queried respondent pharmacys current practice regarding nonprescription sterile syringe sale respondents perception syringe sale counseling practice purchasing syringes Pharmacy pharmacist demographic collected correlation characteristic estimated using unadjusted logistic regression models obtained response 119 pharmacy response rate  34 surveyed pharmacy 81 reported sell syrinx patient without prescription nonmedical uses including intravenous drug use difference whether pharmacy less likely sell syrinx level urbanicity local poverty rate local racialethnic composition pharmacy type ie chain vs independently owned common reason cited selling syrinx security concerns syringe sale encourage drug use corporate policy Among pharmacist pharmacy currently selling syringes 54 aware state law change allowing sale syrinx without medical reason Despite important policy change advancing harm reduction sterile syringe access availability sterile syrinx PWID Georgia pharmacy likely still hampered lack dispensing pharmacies Implementation effort following important policy changesincluding building awareness new policy encouraging support harm reduction efforts continuing education around substance use disordersare essential achieving intended outcome policy",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819053/",
        "source_type": "Global"
    },
    {
        "pmid": "40818720",
        "title": "A novel ionizable lipid with comprehensive improvements in transfection potency, immune profile and safety of lipid nanoparticle.",
        "abstract": "Ionizable cationic lipid critical construction lipid nanoparticles LNPs mRNA delivery Here reported rational design evaluation FS01 novel ionizable cationic lipid incorporating orthobutylphenylmodified hydrophobic tail squaramidebased lipid headgroup architecture Molecular dynamic simulation revealed FS01 enhances mRNA stability ππ stacking interaction aromatic tail nucleobases aromatic rings alongside hydrogen bonding via squaramide headgroup FS01LNPs demonstrated smaller particle size  70 nm high encapsulation efficiency  90  superior mRNA delivery performance across intramuscular subcutaneous intravenous route mouse compared FDAapproved lipid DlinMC3DMA SM102 ALC0315 prophylactic vaccine model Varicellazoster virus Hepatitis B virus FS01LNP formulation elicited robust antigenspecific antibodies memory B cells Th1biased cell responses outperforming benchmark LNPs Further transcriptomic profiling safety assessment demonstrated FS01LNP induced wellbalanced innate immune activation minimal inflammation liver toxicity contrasting pronounced reactogenicity DlinMC3DMA ALC0315 LNPs finding highlighted FS01 promising ionizable lipid candidate mRNA therapeutics offering enhanced delivery efficiency immunogenicity safety potential application extending beyond vaccine gene editing protein replacement therapies",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818720/",
        "source_type": "Global"
    },
    {
        "pmid": "40815495",
        "title": "Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitors.",
        "abstract": "Bruton tyrosine kinase inhibitor BTKis effective welltolerated treatment chronic lymphocytic leukemia CLL mantle cell lymphoma MCL Here describe clinical characteristic hepatitis B virus HBV reactivation patient hematological malignancy treated BTKis Patients required pathologically confirmed diagnosis CLL MCL receive least one cycle ibrutinib zanubrutinib either positive hepatitis B surface antigen hepatitis B core antibody diagnosis Patients excluded received rituximab obinutuzumab within previous 12 months identified five patient CLL one MCL resolved HBV infection received BTKis study period None patient received antiHBV prophylaxis CLL diagnosis patient MCL received zanubrutinib confirmed HBV reactivation even prophylactic entecavir administration followed tenofovir five patient CLL received ibrutinib secondline therapy 62yearold man died hepatorenal syndrome associated HBV reactivation despite entecavir treatment best knowledge first description HBVrelated death patient receiving BTKis HBVendemic areas first case HBV reactivation associated zanubrutinib despite previous entecavir prophylaxis prospective study warranted develop useful guideline monitoring HBV DNA antiviral prophylaxis prevent HBV reactivation BTKi therapy",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40815495/",
        "source_type": "Global"
    },
    {
        "pmid": "40815463",
        "title": "Network controllability analysis reveals the antiviral potential of Etravirine against hepatitis E virus infection.",
        "abstract": "Hepatitis E virus HEV major cause acute viral hepatitis lower middleincome countries HEV infection may lead acute liver failure chronic liver disease high mortality pregnant women Antiviral therapy standard treatment HEV patients Computational biology tool promise revolutionize antiviral drug discovery Here analyzed transcriptome data HEVinfected primary human hepatocyte cell connectivity map database applied control theory functional network identify antiviral target HEV analysis predicted PKCβ PKBAKT CK1ε potential antiviral target HEV antiviral function PKBAKT CK1ε experimentally validated using respective biochemical inhibitor g3 genotype 3HEV replicon Huh7 cellbased model g3 g1HEV infection Furthermore knockdown CK1ε showed similar effect data confirmed CK1ε antiviral target HEV present Food Drug Administration FDAapproved drug targeting CK1ε Etravirine FDAapproved nonnucleoside reverse transcriptase inhibitor drug used treatment AIDS patients iin silicoi study predicted Etravirine potent inhibitor CK1ε experiment revealed potent antiviral activity Etravirine HEV mediated via ability inhibit activity CK1ε Taken together current study demonstrates PKBAKT CK1ε bona fide antiviral target HEV pave way repurposing Etravirine treatment HEVinfected patientsIMPORTANCEAntiviral treatment standard care acute viral hepatitis E patients Unbiased identification antiviral target largescale screening antiviral compound hepatitis E virus HEV reported Here computational biology approach followed unbiasedly identify antiviral target HEV Transcriptome data HEVinfected primary human hepatocyte cell analyzed identify modulators network generate directional networks Network controllability analysis identified PKCβ PKBAKT CK1ε potential antiviral target HEV Antiviral function PKBAKT CK1ε confirmed using cellbased model genotype 1 g1 g3HEV infection experiment demonstrated antiviral activity Etravirine HEV mediated via ability inhibit CK1ε activity Etravirine Food Drug Administrationapproved nonnucleoside reverse transcriptase inhibitor used treatment AIDS patients study reveals potential repurposing Etravirine treatment HEV patient illustrates importance computational biology antiviral drug discovery",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40815463/",
        "source_type": "Global"
    },
    {
        "pmid": "40814512",
        "title": "Clinical spectrum and outcomes of adult varicella (chickenpox) in India.",
        "abstract": "Despite recent rise incidence varicella adult remains underrecognized particularly tropical regions prevalence high study aim delineate clinical spectrum evaluate organ involvement assess outcome adult Indian patient varicella hospitalbased retrospective study conducted Postgraduate Institute Medical Education Research PGIMER Chandigarh India March 2016 February 2020 Adult patient aged ≥15 year diagnosed varicella included Diagnosis based presence characteristic vesicular rash epidemiological history recent exposure exclusion alternative etiologies Fifty patient mean age 32 years 31 males included Organ dysfunction seen 34 68 patients commonly pneumonia ini  17 hepatitis ini  12 hemorrhagic complication ini  12 acute meningoencephalitis myelitis ini  10 Multiorgan involvement present 12 24 Inhospital mortality 18 ini  9 highest among patient pneumonia 412 hemorrhagic complication 417 Advanced age independent predictor mortality OR 1144 iPi value 0034 Twentythree 46 patient underlying predisposing conditions commonly immunosuppressive therapy ini  9 hematological malignancy ini  5 However organ complication outcome comparable regardless immune status one case breakthrough varicella detected Admissions peaked March April ini  15 although case seen throughout year Varicella adult frequently associated severe organ complications particularly pneumonia substantial inhospital mortality adverse outcome occur even previously healthy individuals underscoring need heightened clinical vigilance timely antiviral therapy strengthened preventive strategy adult population",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40814512/",
        "source_type": "Global"
    },
    {
        "pmid": "40814503",
        "title": "Clinico immunological profile of immune-mediated disorders in South Indian children- A prospective observational study.",
        "abstract": "Immunemediated disease affect part body genetically susceptible individuals disease predominantly affect single organ others present multisystemic manifestations collected data clinical demographic immunological detail child immunemediated disease presenting period three year January 2020 December 2022 retrospectively child enrolled Pediatric immunology clinic tertiary care hospital South India prevalence immunemediated disease among child visiting hospital various illness 5 per 1000 children percentage positive autoantibody child connective tissue disorder singleorgan autoimmune disorder 413 407 respectively common connective tissue disorder study juvenile idiopathic arthritis 21 patients among 9  21 428 autoantibody positive ANA common antibody group 475 34 rheumatoid factor positivity connective tissue group common singleorgan autoimmune disorder child autoimmune thyroid disorder 25 followed autoimmune hematological disorder 18 autoantibody common patient thyroid disorder 18  25 autoimmune hepatitis 7  8 Early clinical suspicion prompt diagnosis child prolonged illness atypical presentation essential ensure remission prevent complications morbidity mortality research needed identify early biomarkers immunemediated pediatric disorder help confirm diagnosis guide physician start immunosuppressive therapy right time",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40814503/",
        "source_type": "Global"
    },
    {
        "pmid": "40813841",
        "title": "Investigation of Serum Nitric Oxide, Zinc, Copper, and C-Reactive Protein Levels in Acute Hepatitis B Patients.",
        "abstract": "Acute hepatitis B AHB infection impact million globally causing severe liver disease study aimed assess serum nitric oxide NO Creactive protein CRP copper Cu zinc Zn level interrelationship AHB pathogenesis investigated biomarkers 58 patient AHB 30 healthy controls Results showed patient AHB significantly higher serum level metabolites CRP Cu Zn concentration significantly lower compared control group p  0001 all distinct biomarker profile emerged correlation analysis strong positive correlation found among proinflammatory markers CRP level showing significant positive association Cu rho  0677 total metabolite rho  0631 Conversely serum Zn level exhibited consistent significant negative correlation measured markers notably CRP rho   0649 Cu rho   0520 finding highlight coordinated inflammatory response AHB characterized elevated proinflammatory mediator concurrent depletion essential trace element zinc interconnected biomarker panel underscore significant pathophysiological network hold potential composite tool diagnosis management AHB",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40813841/",
        "source_type": "Global"
    },
    {
        "pmid": "40813740",
        "title": "Deep learning radiomics of elastography for diagnosing compensated advanced chronic liver disease: an international multicenter study.",
        "abstract": "Accurate noninvasive diagnosis compensated advanced chronic liver disease cACLD essential effective clinical management remains challenging study aimed develop deep learningbased radiomics model using international multicenter data evaluate performance comparing twodimensional shear wave elastography 2DSWE cutoff method covering multiple country regions etiologies ultrasound device manufacturers retrospective study included 1937 adult patient chronic liver disease due hepatitis B hepatitis C metabolic dysfunctionassociated steatotic liver disease patient underwent 2DSWE imaging liver biopsy 17 center across China Japan Europe using device three manufacturer SuperSonic Imagine General Electric Mindray proposed generalized deep learning radiomics elastography model integrated elastographic image liver stiffness measurement trained tested stratified internal external datasets total 1937 patient 9472 2DSWE image included statistical analysis Compared 2DSWE model achieved higher area receiver operating characteristic curve AUC 089 v 083 P  0025 also achieved highly consistent diagnosis across subanalyses P values 021091 whereas 2DSWE exhibited different AUCs country region P  0001 etiology P  0005 subanalyses manufacturer subanalysis P  024 model demonstrated accurate robust performance noninvasive cACLD diagnosis 2DSWE across different country regions etiologies manufacturers",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40813740/",
        "source_type": "Global"
    },
    {
        "pmid": "40813475",
        "title": "Segmental Yttrium-90 Radioembolization with Day-of-Calibration Resin Microspheres: Durable Transarterial Ablation for Solitary Hepatocellular Carcinoma.",
        "abstract": "Several recent study report safety efficacy resin yttrium90 radiation segmentectomy localized hepatocellular carcinoma Data informing tumor dose angiosome dose spheresmL required ablativeintent resin radioembolization incomplete safety efficacy dosimetry explant pathology radiation segmentectomy dayof calibration DOC sphere reported Patients identified tertiary care institution received radiation segmentectomy DOC resin 10year period PostY90 dosimetry performed Medical Image Merge MIM Software Imaging response 30day toxicities explant pathology duration response overall survival analyzed Associations dosimetric variable durable response tested receiver operator characteristic Wilcoxon odds ratio analyses Twenty tumor 20 patient treated median size 26 range 1463 cm Fifteen patient 75 male median age 68 range 4888 years Seventeen patient 85 Child cirrhosis 12 hepatitis C 1520 AlBi grade 2 Sixteen singlevessel four doublevessel split dose treatment reached stasis 1724 71 infusions Median tumor angiosome dose 263 range 83649 139 31392 Median lowest dose portion treated tumor 147 29299 Gy Median tumor sphere concentration 79 k 23206 k spheresmL Local modified REsponse Evaluation Criteria Solid Tumors mRECIST response rate 18 90 complete 16 durable one partial response one stable disease Two patient experienced adverse events one grade 3 grade 2 Median followup 20 range 4126 months Median duration response 47 months Median overall survival    94 month without censoring patient transplant six explants demonstrated complete pathologic necrosis Smaller tumor volume associated durable complete response AUC 096 infusion stasis OR 18 95 CI 119 271 Smaller tumor volume lower angiosome dose associated stasis p  0013 0035 Dayof calibration resin segmentectomy treating stasis safe may yield highly durable ablative outcome HCC 3 cm diameter lower dos recommended glass precalibrated resin Y90 Use sphere higher dose target likely warranted larger tumors",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40813475/",
        "source_type": "Global"
    },
    {
        "pmid": "40812556",
        "title": "Fufang Epimedium formula alleviates acute liver injury through dual modulation of PI3K/AKT/Bcl-2 anti-apoptotic signaling pathway and cGAS-STING-IRF3 anti-inflammatory signaling pathway.",
        "abstract": "Fufang Epimedium formula FEF empirical formulation utilized Traditional Chinese Medicine treatment hepatitis B acute liver injury ALI clinical settings far hepatoprotective property underlying mechanism action FEF remain inadequately understood explore effect mechanism FEF treatment ALI Firstly acute oral toxicity FEF extract evaluated using maximum single dose Following 7day pretreatment optimized dos FEF intraperitoneal injection lipopolysaccharide combined  galactosamine administered induce ALI mice component FEF extract well absorbed serum ALI mouse identified using UHPLCQTOFMSMS Subsequently potential active components key target signaling pathway associated FEFs treatment ALI uncovered utilizing network pharmacology conjunction molecular docking effect FEF ALI mice including reduction aminotransferase levels inflammation oxidative stress liver pathology assessed using biochemical assays ELISA kits hematoxylin eosin staining Furthermore mechanism action including inhibiting apoptosis modulating key protein associated PI3KAKTBcl2 cGASSTINGIRF3 pathways confirmed TUNNEL Western blot immunohistochemical assays single oral administration FEF maximum dose 176 gkg result acute toxicity mouse 14day period 479 component FEF extract 138 prototype component ALI mouse serum identified primary component showed binding energy lower 44 kcalmol interacting key target proteins Importantly FEF treatment improved pathological structure damaged liver markedly reduced ALT AST MDA levels increased GSH SOD CAT levels decreasing TNFα IL1β IL6 level ALI mice Furthermore FEF treatment markedly suppressed hepatocyte apoptosis characterized fewer TUNELpositive cells inhibited expression caspase3 PARP enhanced phosphorylation PI3K AKT well increased Bcl2Bax ratio Notably FEF treatment also significantly downregulated cGAS STING expressions suppressed phosphorylation TBK1 IRF3 result confirm FEF exerts hepatoprotective effect reducing aminotransferase levels countering oxidative stress suppressing inflammation preventing apoptosis effect mechanistically linked dual modulation PI3KAKTBcl2 antiapoptotic cGASSTINGIRF3 antiinflammatory pathways finding provide scientific foundation clinical translation FEF future development targeted therapy ALI",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40812556/",
        "source_type": "Global"
    },
    {
        "pmid": "40811846",
        "title": "Updated hepatitis C modelling in Aotearoa New Zealand: a lower burden, but clearer elimination targets.",
        "abstract": "Aotearoa New Zealand progress toward elimination hepatitis C HCV public health threat 2030 updated national modelling provides clearer understanding remaining disease burden treatment targets Using Centre Disease Analysis Foundations Bright model revised earlier estimate reflect declining incidence among people inject drugs treatment uptake new seroprevalence data model estimate approximately 18000 people living viraemic HCV 2023 significantly fewer prior estimates still representing substantial public health challenge Current treatment rate around 450 people per year fall short needed meet World Health Organization target 2030 model suggests treating 1300 people annually required innovative approach expanded access priority groups broader general population strategy may necessary recalibrated model highlight urgency scaling testing improving diagnosis establishing operational target achieve elimination",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40811846/",
        "source_type": "Global"
    },
    {
        "pmid": "40810901",
        "title": "The characteristics of drug users in rehabilitation centers in the West Bank, Palestine: A retrospective descriptive study.",
        "abstract": "Drug abuse pressing global public health issue West Bank Palestine societal stigma around substance use obstructs open conversation precise evaluations underscoring importance thorough assessment drug user rehabilitation facilities study aimed explore epidemiology drug abuse among Palestinian patient rehabilitation center treatment modality employed study examined 1141 medical file patient aged 1473 year two rehabilitation centers covering period 2014 2023 majority 7367 young adult 1839 years tobacco smoker 973 alcohol user 443 Additionally 82 patient diagnosed various infections primarily hepatitis C patient sought treatment voluntarily 782 entering center selfreferral commonly detected substance urine sample cannabis 352 morphine 388 benzodiazepine 328 ecstasy 21 Furthermore 3537 patient prescribed carbamazepine 3071 received methadone 613 struggling adhere prescribed regimens relapse rate high 825 62 patient experiencing three relapses key factor contributing relapse included peer influence withdrawal symptoms analysis treatment modality employed highlighted comprehensive integration pharmacotherapy psychotherapy social support systems emphasizing holistic approach recovery insight derived study aim inform policymakers healthcare provider specific need drug user rehabilitation ultimately contributing enhancement treatment strategy public health initiative region",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40810901/",
        "source_type": "Global"
    },
    {
        "pmid": "40810507",
        "title": "Unexpected Adverse Event caused by Avacopan: A Case of Drug-Induced Hypersensitivity Syndrome in Microscopic Polyangiitis.",
        "abstract": "Microscopic polyangiitis MPA antineutrophil cytoplasmic antibody ANCAassociated vasculitis characterized inflammation small vessels Avacopan oral C5a receptor inhibitor demonstrated efficacy inducing sustaining remission MPA added benefit reducing glucocorticoid exposure associated toxicities Among adverse effects liver injury common occurring 167409 case Japanese cohorts Druginduced hypersensitivity syndrome DIHS rare adverse effect caused avacopan describe case 77yearold woman MPA initiated prednisolone 30 mgday avacopan induction therapy Disease activity MPA improved induction therapy However seven week initiating avacopan developed significant liver dysfunction Despite discontinuation avacopan subsequently presented fever generalized rash leading diagnosis DIHS Laboratory data revealed reactivation human herpesvirus 6 Despite discontinuation avacopan liver injury persisted liver biopsy finding consistent druginduced hepatitis Longterm hospitalization required improvement skin symptom liver function case highlight rare serious adverse event avacopan MPA avacopan therapy necessary monitor delayed severe skin symptom DIHS",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40810507/",
        "source_type": "Global"
    },
    {
        "pmid": "40810215",
        "title": "Treatment Discontinuation and Adherence in Patients With Chronic Hepatitis B Infection Newly Initiating Nucleos(t)ide Analogues in Japan: A Retrospective Cohort Study.",
        "abstract": "Nucleostide analogue NA therapy current standard care chronic hepatitis B CHB virus infection rarely achieves functional cure necessitating longterm therapy often lead nonadherence increased treatment burden retrospective cohort study designed describe treatment discontinuation adherence secondgeneration NAs among patient CHB Japan used Japanese Medical Data Center Claims Database JMDC Inc identify adult CHB newly initiated singleagent secondgeneration NA January 2007 August 2023 Outcomes included treatment discontinuation adherence treatment restart discontinuation NA switching factor associated treatment discontinuationadherence 2473 patient included study mean age 499 years 656 male common index NAs entecavir 555 tenofovir alafenamide fumarate TAF 362 Treatment discontinuation observed 203 patients mean time discontinuation 204 months patient discontinued 507 restarted NAs Mean adherence proportion day covered PDC 087 812 participant PDC ≥ 80 Age group 3564 years index treatment TAF baseline hepatocellular carcinoma diagnosis significantly associated decreased probability treatment discontinuation nonadherence Although high proportion patient persistent adherent NA treatment subgroup patient whose need met receiving NA treatment particularly younger age groups result emphasise need alternative therapy shorter finite treatment duration improve patient persistence adherence outcomes",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40810215/",
        "source_type": "Global"
    },
    {
        "pmid": "40810105",
        "title": "Navigating liver toxicity in the age of novel oncological agents.",
        "abstract": "advent novel oncological therapies including immune checkpoint inhibitors antibodydrug conjugates protein kinase inhibitors revolutionised cancer treatment significantly improving patient survival across range malignancies However advance accompanied emergence new often unpredictable adverse events among hepatotoxicity represents growing clinical challenge review provide comprehensive synthesis current knowledge liver injury associated three key class oncological agents particular focus mechanism action hepatotoxicity clinical presentation management strategies Given expanding use agents monotherapies combination regimens topic pressing relevance hepatologists oncologist alike combination therapy become increasingly common complexity drugliver interaction implication patient safety demand greater interdisciplinary awareness collaboration review advocate pragmatic approach management druginduced liver injury patient cancer underscoring critical need balance hepatic preservation imperative maintaining oncological efficacy uniquely vulnerable population addressing emerging area clinical importance aim stimulate research oncological hepatotoxicity phenomenon poised become increasingly prevalent routine clinical practice",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40810105/",
        "source_type": "Global"
    },
    {
        "pmid": "40808966",
        "title": "Safety and efficacy of GST-HG141, a novel HBV capsid assembly modulator, for the treatment of chronic hepatitis B patients with low-level viremia: a randomized, double-blind, placebo-controlled, multicenter phase II study.",
        "abstract": "Chronic hepatitis B CHB remains major global health challenge curative therapies Approximately 1540 patient treated current standardofcare antiviral therapy nucleostide analog NUCs including entecavir ETV tenofovir TDFTAF fail fully suppress serum HBV DNA resulting persistent lowlevel viremia LLV associated increased risk cirrhosis liver failure hepatocellular carcinoma GSTHG141 novel HBV capsid assembly modulator previously demonstrated favorable safety antiviral activity Phase Ib study offering promising approach LLV management CHB patients Phase II randomized doubleblind placebocontrolled multicenter trial evaluated efficacy safety GSTHG141 CHB patient LLV registered ClinicalTrialsgov NCT05637541 Clinical Trial Registry GSTHG141II02 January 2023 July 2024 144 patient screened across ten research center China 90 eligible participant enrolled participant NUC therapy one year serum HBV DNA level 20 2000 IUmL ALT ≤5 × ULN Patients randomized 111 receive lowdose GSTHG141 50 mg BID ini  30 highdose GSTHG141 100 mg BID ini  30 placebo ini  30 administered orally 24 weeks primary endpoint proportion participant achieving serum HBV DNA level lower limit detection 20 IUmL Week 24 Secondary endpoint included change HBV DNA level virological marker baseline 4week followup phase assessed safety sustained virologic response total 89 patient received least one dose study medication enrolled Among them eighty patient completed treatment included perprotocol analysis 25 lowdose group 27 highdose group 28 placebo group GSTHG141 significantly reduced serum HBV DNA level CHB patient suboptimal response prior NUC therapy week 24 840 patient lowdose group 815 highdose group achieved HBV DNA 20 IUmL compared 321 placebo group ipi  005 treatment group vs placebo Mean HBV DNA reduction exceeded 1 logsub10sub IUmL GSTHG141groups Additionally pregenomic RNA pgRNA level also declined average 17 logsub10sub copiesmL 60 55 participant low highdose groups respectively achieving undetectable pgRNA compared 95 placebo group Safety profile favorable good tolerability comparable adverse event across groups GSTHG141 administered orally 50 100 mg BID safe welltolerated highly effective suppressing residual HBV DNA pgRNA level CHB patient LLV result support development GSTHG141 novel therapeutic option CHB patient inadequately responding conventional NUC treatment work supported Fujian Akeylink Biotechnology Co Ltd",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40808966/",
        "source_type": "Global"
    },
    {
        "pmid": "40806558",
        "title": "Unravelling the Viral Hypothesis of Schizophrenia: A Comprehensive Review of Mechanisms and Evidence.",
        "abstract": "Schizophrenia challenging multifactorial neuropsychiatric disease involves interaction genetic susceptibility environmental insults Increasing evidence implicates viral infection significant environmental contributors particularly sensitive neurodevelopmental periods review synthesis current finding viral hypothesis schizophrenia encompassing wide array neurotropic viruses including influenza viruses herpesviruses HSV1 2 CMV VZV EBV HHV6 8 hepatitis B C viruses HIV HERVs HTLV Zika virus BoDV coronaviruses including SARSCoV2 others pathogen contribute schizophrenia mechanism direct microinvasion persistent central nervous system infection immunemediated neuroinflammation molecular mimicry disturbance bloodbrain barrier Prenatal exposure viral infection trigger maternal immune activation resulting cytokinemediated alteration neurological development foetus persist adulthood Genetic study highlight role immunerelated loci including major histocompatibility complex polymorphisms modulating susceptibility infection neurodevelopmental outcomes Clinical data also support mild encephalitis hypothesis suggesting subset schizophrenia case involve lowgrade chronic neuroinflammation Although antipsychotic immunomodulatory effects adjunctive antiinflammatory therapy show promise particularly treatmentresistant cases Despite compelling associations pathogenspecific link remain inconsistent emphasising need longitudinal study integrative approach viromics unravel causal relationships review support multihit model viral infection interfere hereditary immunological susceptibilities enhancing schizophrenia risk Elucidating virusimmunebrain interaction may facilitate discovery biomarkers targeted prevention novel therapeutic strategy schizophrenia",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40806558/",
        "source_type": "Global"
    },
    {
        "pmid": "40806504",
        "title": "Real-Time PCR-Based Detection of Hepatitis E Virus in Groundwater: Primer Performance and Method Validation.",
        "abstract": "Hepatitis E virus HEV leading cause acute viral hepatitis primarily transmitted via contaminated water food Groundwater may also serve potential vector HEV transmission study aimed optimize realtime polymerase chain reaction rtPCR detection HEV employing TaqMan probe SYBR Greenbased methods total 12 primer set TaqMan probebased method 41 primer set SYBR Greenbased method evaluated order identify optimal combinations Primer set 4 TaqMan probebased 21 SYBR Greenbased demonstrated highest sensitivity specificity successfully detecting HEV artificially spiked sample 1 fgμL TaqMan probebased method facilitated rapid detection minimized nonspecific amplification whereas SYBR Greenbased method allowed broader primer exploration leveraging melting curve analysis Despite absence HEV detection 123 groundwater samples study underscore value realtime PCR environmental monitoring pave way enhanced diagnostic tool public health applications",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40806504/",
        "source_type": "Global"
    },
    {
        "pmid": "40806358",
        "title": "Exploring Cirrhosis: Insights into Advances in Therapeutic Strategies.",
        "abstract": "Cirrhosis remains significant global health burden responsible nearly 4 annual death worldwide Despite progress antiviral therapy public health measures prevalence plateaued particularly region affected viral hepatitis alcohol misuse metabolic syndrome review present comprehensive synthesis multifactorial driver cirrhosis including hepatocyte injury liver stellate cell activation immunemediated inflammation emphasis central role metabolic dysfunction characterized mitochondrial impairment altered lipid glucose metabolism hormonal imbalance systemic inflammation exacerbating disease progression current therapy may slow progression earlystage disease often ineffective reversing established fibrosis Emerging molecular strategy offer promising alternative targeting key pathogenic pathways include AMPK activator eg metformin AICAR FGF21 analogs mitochondriatargeted agent eg MitoQ urolithin A NAD precursors restore bioenergetic balance reduce oxidative stress approaches mesenchymal stem cell therapy inflammasome inhibition hormonal modulation aim suppress fibrogenesis restore liver homeostasis integration system biology multiomics profiling support patient stratification precision medicine review highlight shift toward mechanismbased intervention potential alter cirrhosis outcome improve patient survival",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40806358/",
        "source_type": "Global"
    },
    {
        "pmid": "40805232",
        "title": "The Exposome Perspective: Environmental and Infectious Agents as Drivers of Cancer Disparities in Low- and Middle-Income Countries.",
        "abstract": "Cancer disparity low middleincome country LMICs arise multifaceted interaction environmental exposures infectious agents systemic inequities limited access care exposome framework encompassing totality nongenetic exposure throughout life offer powerful lens understanding disparities LMICs population disproportionately affected air water pollution occupational hazards oncogenic infections including human papillomavirus HPV hepatitis B virus HBV iHelicobacter pylorii iH pylorii human immunodeficiency virus HIV neglected tropical diseases schistosomiasis infectious agent contribute increased cancer susceptibility poor outcomes particularly immunocompromised individuals Moreover climate change food insecurity barrier healthcare access exacerbate risks review adopts populationlevel exposome approach explore environmental infectious exposure intersect genetic epigenetic immune mechanism influence cancer incidence progression LMICs highlight critical pathway linking chronic exposure inflammation tumor development evaluate strategy HPV HBV vaccination antiretroviral therapy environmental regulation Special attention given tool exposomewide association study ExWASs offer promise exposure surveillance early detection public health policy integrating exposomic insight national health systems especially region subSaharan Africa SSA South Asia LMICs advance equitable cancer prevention control strategies holistic exposomeinformed strategy essential reducing global cancer disparity improving outcome vulnerable populations",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40805232/",
        "source_type": "Global"
    },
    {
        "pmid": "40805161",
        "title": "Late-Onset Immune-Related Adverse Events in Patients with Advanced Melanoma: The LATENT Study.",
        "abstract": "Immune checkpoint inhibitor significantly transformed treatment paradigm advanced melanoma leading substantial improvement survival outcomes However therapeutic success accompanied spectrum treatmentrelated adverse events increasingly recognised enduring nonreversible Whilst earlyonset immunerelated toxicity well characterized lateonset toxicities often emerging patient longterm disease control remain understudied frequently overlooked address knowledge gap conducted retrospective multicentre study three UK tertiary referral centres exploring immunerelated adverse event 246 patient melanoma received immune checkpoint inhibitor advanced setting defined lateonset immunerelated adverse event occurring least 3 month last cycle immune checkpoint inhibitors Although patient experienced earlyonset toxicity almost 15 patient developed lateonset immunerelated adverse events including skin rash colitis hepatitis arthritis among others often challenging manage necessitated use systemic steroids 2 patient presented ultralateonset toxicities defined event occurring least 12 month treatment completion study provides valuable insight characteristic lateonset immunerelated adverse events advance understanding lateonset toxicities dedicated prospective study needed assess risk factor associated development impact quality life Additionally translational research focused finding predictive biomarkers essential identify patient higher risk developing delayed adverse event understand best manage them",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40805161/",
        "source_type": "Global"
    },
    {
        "pmid": "40803751",
        "title": "Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial.",
        "abstract": "SCG101 autologous Tcell therapy specifically targeting hepatitis B virus HBV using natural highaffinity Tcell receptor stably expressed evaluated safety pharmacokinetics pharmacodynamics efficacy SCG101 patient HBVrelated hepatocellular carcinoma HCC investigatorinitiated trial Six human leucocyte antigen HLAA0201positive serum hepatitis B surface antigen HBsAgpositive hepatitis B e antigennegative patient advanced HBVHCC failed one three prior systemic therapies received SCG101 dos 5×10sup7sup 1×10sup8sup TCRTsupsup cellskg three day lymphodepletion Within 1 week patient experienced significant transient alanine aminotransferase elevation paralleled 76±57 fold expansion cell detected peripheral blood neurotoxicity cytokine release syndrome reaching grade 3 observed However side effect doselimiting could managed corticosteroids antiinterleukin6 andor vasopressor therapy Indicating ontarget activity SCG101 serum HBsAg level dropped 196 016384 logsub10sub within 2 weeks According modified Response Evaluation Criteria Solid Tumours three six patient achieved tumour shrinkage best percentage change target lesion size 195 746 100 One showed complete remission target lesion remaining progressionfree 27 month one achieved durable 6 months remission followup median 109 months three patient died one lost followup monotherapy patient HBVHCC SCG101 demonstrated pronounced antiviral antitumour activity safety profile manageable supportive care SCG101s Tcell expansion serum HBsAg drop tumour response collectively underscore ontarget activity NCT05339321",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40803751/",
        "source_type": "Global"
    },
    {
        "pmid": "40803709",
        "title": "Cytomegalovirus hepatitis after treatment with dostarlimab for colorectal cancer.",
        "abstract": "man early 40 receiving treatment rectal cancer dostarlimab immune checkpoint inhibitor ICI developed fevers headache nausea hospitalised elevated liver enzyme infectious workup revealed acute cytomegalovirus CMV infection concern dostarlimab therapy could contributing inflammatory response ICIinduced hepatitis patient underwent liver biopsy Pathology instead consistent CMV hepatitis patient treated antiviral therapy complete resolution illness case illustrates importance monitoring immunerelated adverse effect patient taking ICIs still maintaining broad differential diagnosis causes",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40803709/",
        "source_type": "Global"
    },
    {
        "pmid": "40803501",
        "title": "Targeting ferroptosis restores the antiviral activity of CD8<sup>+</sup> T cells during chronic HBV infection.",
        "abstract": "CD8supsup cell play crucial role antiviral immunity however hepatitis B virus HBVspecific CD8supsup cell become dysfunctional chronic HBV CHB infection Blocking inhibitory pathway partially restores efficient antiviral responses suggesting mechanism underlying CD8supsup Tcell dysfunction complicated study aimed investigate whether HBVspecific CD8supsup cell undergo ferroptosis examine correlation Tcell dysfunction elucidate underlying mechanism potential intervention strategies Analysis CD8 cell CHB patient revealed ferroptosis marker via flow cytometry electron microscopy scRNAseq HBVspecific CD8supsup cell identified using HBVcore antigen peptideloaded MHC tetramer Flow cytometry scRNAseq additional experimental approach employed investigate ferroptosisassociated mechanism CD8supsup Tcell dysfunction Ferroptosis observed CD8supsup cell CHB patients indicated increased lipid peroxidation Fesup2sup accumulation mitochondrial atrophy particular HBVspecific CD8supsup cells Downregulation GPX4 upregulation CD36 found CD8supsup cell high level lipid peroxidation Furthermore ferroptosis accompanied impaired antiviral ability Mechanistically palmitic acid PA upregulates CD36 expression leading lipid accumulation elevated serum TGFβ1 CHB patient reduces GPX4 expression impairs antioxidant capacity factor synergistically promote ferroptosis dysfunction CD8supsup cells Treatment selenium liproxstain1 enhanced cytotoxic cytokine production CD8supsup cells subsequently improved antiviral efficacy vivo study demonstrates ferroptosis drive CD8supsup Tcell dysfunction chronic HBV infection Targeting ferroptosis pathway may offer novel therapeutic strategy restore antiviral immunity",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40803501/",
        "source_type": "Global"
    },
    {
        "pmid": "40802985",
        "title": "CROI 2025: The Challenges of Sustaining Viral Suppression, Addressing Advanced HIV Disease, and Ending the HIV Epidemic Targets.",
        "abstract": "Important new data presented 2025 Conference Retroviruses Opportunistic Infections Mathematic model predicted reversal progress toward Ending HIV Epidemic metric funding discontinued Interventions improved HIV care outcome included clinicbased personcentered care intervention lowbarrier care clinic service delivery model Several study demonstrated varying trend hepatitis B C incidence outcomes data one trial showed seroprotective durability adjuvanted hepatitis B vaccine people HIV Focus continued longacting antiretroviral therapy ART including data promising new agent formulations Integrase strand transfer inhibitor InSTIs may effective real world despite baseline reverse transcriptase resistance although 2 study highlighted emergence mutation outside integrase genome contribute InSTI resistance data HIV maternal pediatric health included study aimed HIV testing counseling also covered drug interaction implant injectable hormonal contraceptive dolutegravirbased ART along selected pharmacokinetics safety data ART infant children Various abstract addressed weight gain cardiometabolic dysfunction youth perinatally acquired HIV woman HIV well health outcome child exposed HIV ART utero",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40802985/",
        "source_type": "Global"
    },
    {
        "pmid": "40802699",
        "title": "Hepatitis A beyond childhood causing diagnostic and therapeutic challenges in Addis Ababa, Ethiopia.",
        "abstract": "Hepatitis acute viral infection liver caused hepatitis virus HAV acquired fecooral route highest incidence among four major acute viral hepatitis type A B C E usually occurs early childhood However prevalence acute hepatitis recently increased among teenager young adults usually misdiagnosed study emphasizes significance awareness among healthcare worker increasing incidence acute hepatitis among group ensure accurate diagnosis appropriate management hospitalbased retrospective crosssectional study employed Fiftyeight confirmed acute HAV patient visited Adera Medical Surgical Center AMSC August 2023 January 2024 enrolled Sociodemographic clinical laboratory parameter documented management data including hospitalization trial antibiotic treatment considering HAV course illness collected data entered analyzed using SPSS SPSS Version 260 sex ratio similar slight male predominance MF  107 mean age ± SD patient 193± 88 years Thirtynine 672 patient students patient Addis Ababa Vomiting 828 anorexia 707 yellowish discoloration eye 621 common presenting symptoms icteric sclera 44 759 epigastric tenderness 17 293 common physical findings half patient 552 initially misdiagnosed typhoid fever TF 468 peptic ulcer disease PUD 312 urinary tract infection UTI 156 patient recovered fully liver function test LFTs normalized supportive care within 24 weeks study revealed shift age HAV susceptibility subsequent infection towards adolescent young adult mean ± SD age 1931 ± 88 years cohort half patient 552 initially misdiagnosed TF PUD UTI causing diagnostic treatment challenges necessitates heightened awareness among healthcare worker public Early HAV diagnosis targeted laboratory investigation avoiding unnecessary antibiotic crucial effective management prevention via hygienic immunization strategies",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40802699/",
        "source_type": "Global"
    },
    {
        "pmid": "40802610",
        "title": "Molecular surveillance of hepatitis E virus in wastewater in Yaoundé, Cameroon.",
        "abstract": "Hepatitis E virus HEV zoonotic pathogen mainly transmitted contaminated food water subSaharan countries highlighting need environmental surveillance study aimed assess burden molecular characterization HEV environmental wastewater communitybased surveillance conducted Yaoundé Cameroon using untreated wastewater sample collected monthly January December 2023 hospitals residential sewage systems markets plant watering points Molecular phylogeny performed sequence Open Reading Frame 1 region HEV detected 264 1972 sites prevalence ranging 83 112 hospital 417 512 residential area p  00022 19 positives HEV detection highest specific residential area 263 plant watering point 158 Detection rate significantly higher short dry season 368 long dry season 316 compared shortwet season 2105 longwet season 1053 p  0034 Phylogenetic analysis sequenced sample revealed detected HEV strain closely related Orthohepevirus C genotype C1 previously associated rodent rather classical human HEV genotypes finding raise important question possible zoonotic transmission densely populated urban areas first study report HEV detection genetic analysis wastewater Mfoundi Division Yaoundé second report Cameroon presence HEV community wastewater especially residential irrigation sites suggests widespread circulation potential environmental foodborne risks identification HEVC1like strain highlight possible role rodent transmission finding emphasize importance integrating wastewater surveillance public health strategy call research zoonotic source One Health lens",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40802610/",
        "source_type": "Global"
    },
    {
        "pmid": "40802556",
        "title": "Deep-Learning-Aided Quantification of Steatohepatitis-Associated Pathological Findings in Liver Specimens.",
        "abstract": "Although semiquantitative scoring common method quantifying histopathological findings semiquantitative evaluation may lead error objectivity reproducibility depending histological findings developed deep learning model quantify steatohepatitisassociated pathological finding liver specimens Eighteen liver specimen steatohepatitis eight liver specimen chronic hepatitis used train AI convolutional neural network construct AI quantify steatohepatitisassociated pathological findings AI model measured percentage steatosis area Steatosis ballooning area Ballooning fibrosis area Fibrosis liver biopsy specimens Subsequently 233 patient underwent ultrasonography liver biopsy used validation Histological finding liver specimen evaluated three evaluator expertise liver pathology Steatosis Ballooning Fibrosis measured liver specimens patients Steatosis strongly correlated histological steatosis grade R  078 p  0001 ultrasound controlled attenuation parameter R  051 p  0001 liver tissue 47 nonalcoholrelated steatotic liver disease NASLD patients Ballooning correlated histological ballooning grade R  04 p  001 NASLD patients Fibrosis strongly correlated histological fibrosis stage R  072 p  0001 ultrasound shear wave elastography R  07 p  0001 Deeplearningaided pathology quantify steatohepatitisassociated pathological finding liver tissue specimens AI model tool used quantify steatohepatitisassociated pathological finding algorithm diagnose steatohepatitis",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40802556/",
        "source_type": "Global"
    },
    {
        "pmid": "40802226",
        "title": "Synbiotics: An Emerging Frontier in Infectious Diseases Control.",
        "abstract": "human gut microbiome critical promoting human health many aspects like facilitating nutrient absorption digestion immune system regulation protecting pathogens Gut microbiota dysbiosis associated pathogenesis several infectious diseases context combination prebiotics probiotic synbiotics emerging popular approach managing immune gastrointestinal health Synbiotics exhibited considerable potency restoring eubiosis via modulating gut microbiome dietary supplementation synbiotics shown promising result treating infectious disease like hepatitis gastroenteritis dental caries sepsis Synbiotics antagonise pathogen maintaining gut microbiota homeostasis competing pathogenic microorganism adhesion nutrition producing antimicrobial compounds stimulating immunomodulatory cell vivo present article conceptualised understand potential synbiotics alternative adjunct antibiotic managing infectious diseases Furthermore elaborates different formulation synbiotics available clinical use mode action Challenges associated recent approach improve efficacy therapeutic also addressed",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40802226/",
        "source_type": "Global"
    },
    {
        "pmid": "40800185",
        "title": "Functional cure in a child with chronic hepatitis B with rtM204I mutation through an atypical serological response: a case report.",
        "abstract": "rtM204I mutation commonly associated resistance nucleostide analog NA therapy hepatitis B virus HBV often resulting virological breakthrough treatment failure Owing unique immunological virological characteristic HBV achieving functional cure pediatric patient easier adults case involving concurrent drugresistant mutation rare 4yearold boy infected HBV mothertochild transmission experienced virological rebound HBV DNA 466×107 IUmL 12 month lamivudine LAM monotherapy Resistance testing revealed rtM204I mutation treatment regimen adjusted tenofovir disoproxil fumarate TDF combined pegylated interferon α2a PegIFNα2a 12 week treatment significant decline hepatitis B surface antigen HBsAg level accompanied positive antibody hepatitis B surface antigen antiHBs thus presenting atypical serological pattern double positivity HBsAg antiHBs week 24 HBsAg negative hepatitis B e antigen HBeAg remained positive demonstrating atypical serological pattern response dissociation whereby HBsAg disappeared HBeAg TDF combined PegIFNα2a administered week 36 resulting persistent HBsAg negativity significant increase antiHBs levels PegIFNα2a discontinued TDF monotherapy continued 10 months period HBsAg negativity antiHBs positivity maintained HBeAg became negative alanine aminotransferase level remained normal result indicate achievement functional cure case indicated child rtM204I mutation optimizing antiviral therapy combined PegIFNα2a achieve functional cure despite atypical serological response patterns Longacting interferon significant therapeutic value pediatric patient drugresistant mutations",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40800185/",
        "source_type": "Global"
    },
    {
        "pmid": "40800168",
        "title": "A retrospective study of clinical characteristics and steroid therapy in immune checkpoint inhibitor-mediated hepatitis.",
        "abstract": "widespread clinical application immune checkpoint inhibitor ICIs immunemediated hepatitis IMH become increasingly prevalent study aim analyze clinical characteristics steroid treatment prognosis IMH patients providing evidence enhance safety ICIs clinical practice retrospective cohort study included tumor patient received ICI therapy Comprehensive analysis conducted explore factor influencing occurrence clinical characteristics prognosis IMH Tumor patient treated PD1PDL1 inhibitor enrolled study Patients stratified based occurrence severity IMH well administration glucocorticoid therapy investigate risk factor IMH development critical factor influencing IMH progression treatmentspecific outcomes 744 patients 341 458 developed IMH IMH significantly frequent female ipi  0001 younger patient ipi  0001 receiving ICIs targeted therapy ipi  0009 patient hepatocellular carcinoma HCC ipi  0001 gastric cancer ipi  0001 Coexisting hepatitis B ipi  0001 cirrhosis ipi  0005 fatty liver disease ipi  0028 also associated higher IMH risk Independent risk factor included female gender age 45 years HCC gastric cancer Younger patient likely develop severe IMH ipi  0003 Hepatocellular injury common type IMH across grades similar risk severe progression among different IMH types Glucocorticoid therapy improved outcome ipi  0011 particularly grade 34 IMH although significant difference outcome observed group receiving sufficient versus insufficient recommended doses Female gender younger age 45 years HCC gastric cancer independent risk factor IMH Younger patient likely develop severe IMH Glucocorticoid therapy beneficial particularly grade 34 IMH Early detection prompt intervention tailored management strategy may help mitigate progression improve outcomes",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40800168/",
        "source_type": "Global"
    },
    {
        "pmid": "40799938",
        "title": "Detecting early kidney injury due to host-virus interaction response in treatment-naive CHB-a pilot study.",
        "abstract": "Clinical evidence suggests patient chronic hepatitis B CHB increased risk renal impairment due inflammation induced virushost interaction aimed evaluate validate set protein biomarkers singularly combination early detection subclinical kidney injury patient CHB naive antiretroviral therapy work part prospective crosssectional study 69 HBsAgpositive treatmentnaive patient CHB equal number agematched healthy volunteer considered diagnosis serum creatinine sCr urea alanine transaminase aspartate transaminase serum cystatinC sCysC serum neutrophil gelatinaseassociated lipocalin sNGAL serum FetuinA sFetA urinary interleukin18 binding protein uIL18BP urinary kidney injury molecule1 uKIM1 level determined significant elevation concentration three protein CHB cohort sCysC sNGAL uIL18BP ipi  00001 sFetA downregulated ipi001 compared control group receiver operating characteristic curve analysis revealed Area curve 0935 sCysC 0811 sNGAL improved 0984 four indicator combined panel discriminate onset renal injury incited inflammatory response CHB 971 sensitivity 913 specificity Additionally sCysC sNGAL differed significantly among phase CHB infection ipi005 novel noninvasive diagnostic screen expedient detecting inflammation early kidney injury rise sCr aid predicting renal outcome patient CHB",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40799938/",
        "source_type": "Global"
    },
    {
        "pmid": "40799791",
        "title": "Hepatitis C Treatment Outcomes for Patients With Infective Endocarditis Treated by an Interdisciplinary Team.",
        "abstract": "Patients endocarditis often comorbid injection substance use risk hepatitis C virus HCV infection population may encounter several significant barrier treatment improve access treatment developed interdisciplinary collaboration specialty pharmacy University Kentucky endocarditis team conducted retrospective study evaluating treatment outcomes Beginning September 2021 endocarditis team worked specialty pharmacy connect inpatient endocarditis HCV expedited treatment coordinated outpatient followup Study investigator retrospectively reviewed data consisting patient demographic treatment outcomes September 2021 April 2024 64 patient infective endocarditis HCV identified median age 37 years 41 female 97 history injection drug use Upon discharge 75 48 64 initiated treatment Treatment completed 69 33 48 patients main reason discontinuation included loss followup n  10 medication side effect n  3 Sustained virologic response 12 week achieved 42 n  20 patient initiated treatment 31 patients Among 22 patient available laboratory result 12 week posttreatment 91 n  20 HCV RNA negative Despite effort promoting expedited treatment interdisciplinary coordination care sustained virologic response rate patient endocarditis HCV infection remained 40 research required determine intervention starting therapy inpatient stay immediately upon discharge dispensing entire course medication improve treatment outcomes",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40799791/",
        "source_type": "Global"
    },
    {
        "pmid": "40799641",
        "title": "The role of HLA-G in primary biliary cholangitis and response to therapy.",
        "abstract": "Primary biliary cholangitis PBC rare autoimmune liver disease involving bile duct damage fibrosis study explores role HLAG immunomodulatory molecule crucial immune tolerance PBC pathogenesis treatment cohort 166 PBC patient Sardinia compared 180 healthy control 205 autoimmune hepatitis type 1 AIH1 patients Plasma soluble HLAG sHLAG levels iHLAGi alleles i3UTRi haplotype analyzed alongside clinical data including therapy response ursodeoxycholic acid UTR1 haplotype significantly frequent PBC patient control 482 v 343 Pc 00018 extended haplotype iHLAG01010108UTR1i also strongly associated PBC 232 v 125 controls Pc  0008 232 v 66 AIH1 Pc 26×10sub9sub PBC patient exhibited lower sHLAG level compared control AIH1 91 UmL v 2403 UmL 139 UmL respectively Among iUTR1i carriers sHLAG level particularly reduced PBC patients iHLAG01010108UTR1i haplotype correlated lowest sHLAG level poorer therapy response 60 v 241 P  00001 finding suggest HLAG variants especially iHLAG01010108UTR1i potential biomarkers PBC prognosis treatment outcomes",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40799641/",
        "source_type": "Global"
    },
    {
        "pmid": "40799509",
        "title": "MVA-HBVac-A novel vaccine vector that allows pan-genotypic targeting of hepatitis B virus by therapeutic vaccination.",
        "abstract": "Therapeutic vaccination hold promise cure chronic hepatitis B virus HBV infection hypothesize B cell CD4 CD8 cell response necessary overcome HBVspecific immune tolerance chronic infection accompany rare spontaneous resolution chronic HBV infection Therefore designed heterologous primeboost vaccine iTherVacBi viruslike particle vaccination stimulates B helper CD4 cell prime cytotoxic effector CD8 cell vector boost expands cell response Here report generation characterization novel modified vaccinia virus Ankara MVAbased vector MVAHBVac capable inducing strong multispecific cell response immunodominant epitope four different viral protein covering 95 HBV strain circulating worldwide MVAHBVac administered prime adjuvanted hepatitis B S coreantigens forming viruslike particles activated strong HBVspecific CD4 CD8 cell response major HBV antigen iin vivoi naive HBV carrier mice induced sustained antiviral effect different clinically relevant HBV genotypes data showed iTherVacBi regimen employing novel pangenotypic MVAHBVac vector could overcome HBVspecific immune tolerance lead initiation clinical trial evaluating therapeutic vaccine",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40799509/",
        "source_type": "Global"
    },
    {
        "pmid": "40799443",
        "title": "Successful rechallenge of immune checkpoint inhibitors after severe immune-related hepatitis, thyroiditis and hypophysitis in TMB-high NSCLC: a case report.",
        "abstract": "Immune checkpoint inhibitor ICIs transformed cancer therapy frequently associated immunerelated adverse event irAEs complicate treatment decisions Patients experience severe irAEs often excluded immunotherapy due concern recurrence However rechallenging ICIs selected patient close monitoring may offer longterm benefits although evidence remains limited heterogeneous report case 65yearold man stage IVB pulmonary adenocarcinoma harboring iTP53i mutation high tumor mutational burden initially received pembrolizumabbased chemoimmunotherapy developed grade 4 hepatitis requiring immunosuppressive treatment discontinuation ICIs Subsequent tumor progression led rechallenge ICIs alongside prophylactic tocilizumab Although patient experienced grade 2 thyroiditis grade 2 hypophysitis toxicity manageable hormone replacement corticosteroids pacemaker implanted unrelated sick sinus syndrome Despite intermittent symptoms pembrolizumab monotherapy maintained prolonged period achieving durable tumor control progression noted 4year followup case highlight ICI rechallenge viable effective treatment strategy selected patient prior highgrade irAEs especially initial toxicity well controlled alternative cause symptom carefully excluded prophylactic use agent like tocilizumab may reduce risk irAE recurrence underscore need individualized riskbenefit assessment close clinical monitoring rechallenge scenarios",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40799443/",
        "source_type": "Global"
    },
    {
        "pmid": "40797383",
        "title": "Immune deficiency due to SARS-CoV-2 infection in a child with GATA2-mutated AML: A case report.",
        "abstract": "Mutations guanineadeninethymineadenine 2 GATA2 gene lead immunodeficiency haematological diseases including acute myeloid leukaemia AML Severe acute respiratory syndrome coronavirus 2 SARSCoV2 infection reported impair immune function effect GATA2 mutation carrier remain unclear study report rare case persistent immunodeficiency child AML GATA2 mutation SARSCoV2 infection emphasizing role viral infection immune dysfunction patients 9yearold AML patient developed fever cough persistent immunodeficiency recurrent severe infection SARSCoV2 infection haematological remission patient diagnosed AMLM2 germline GATA2 mutation chemotherapy achieved haematological remission SARSCoV2 infection showed significant immunodeficiency manifestation recurrent infections patient received combined chemotherapy based CALSIIIAML18 achieved haematological remission SARSCoV2 infection comprehensive treatment  example antiviral Paxlovid antibacterial antifungal hormonal therapy  used support immune function patient completed HLA matching allogeneic hematopoietic stem cell transplantation scheduled undergo transplantation Despite various immune support treatment SARSCoV2 infection patient still persistent immune deficiency recurrent infection eg pneumonia hepatitis B patient currently stable waiting hematopoietic stem cell transplantation AML patient GATA2 mutation achieve remission SARSCoV2 infection may still trigger severe persistent immunodeficiency leading serious infection affecting prognosis Therefore early identification GATA2 mutation early implementation hematopoietic stem cell transplantation key improving prognoses",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40797383/",
        "source_type": "Global"
    },
    {
        "pmid": "40795893",
        "title": "Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries with the Highest Adult HIV Prevalence.",
        "abstract": "Expanded access dolutegravir part fixeddose combination tenofovir disoproxil fumarate lamivudine TLD revolutionized global HIV treatment 25 million people prescribed regimen 2024 reviewed national clinical guideline management virologic failure firstline TLD 50 country highest prevalence HIV among adults recent guideline available online four Among remaining 46 country guidelines identified four distinct approaches 1 empiric switch protease inhibitor PIbased regimen without genotypic resistance testing GRT n28 61 2 GRT guide antiretroviral therapy selection n14 30 3 continuation TLD without GRT n3 7 4 empiric switch PIbased regimen concurrent GRT n1 2 diversity guidelineendorsed approach underscore critical need additional data inform policy regarding important clinical scenario",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40795893/",
        "source_type": "Global"
    },
    {
        "pmid": "40795873",
        "title": "Sofosbuvir/Velpatasvir Concentrations in the Breastmilk of Postpartum Women with Opioid Use Disorder Receiving Treatment for Hepatitis C Virus: a pharmacokinetic study.",
        "abstract": "breastmilk pharmacokinetic study woman undergoing hepatitis C virus treatment sofosbuvirvelpatasvir sofosbuvir GS331007 sofosbuvir metabolite velpatasvir concentration breast milk 13 12 41 maternal plasma concentrations respectively estimated infant daily dose breastmilk 1 weightadjusted dose children",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40795873/",
        "source_type": "Global"
    },
    {
        "pmid": "40794751",
        "title": "Non-negligible risk of HBV reactivation among rheumatoid arthritis patients receiving JAK inhibitors: bridging the evidence gap.",
        "abstract": "Hepatitis B virus HBV reactivation critical concern patient autoimmune disease undergoing immunosuppressive therapy Despite data HBV reactivation risk associated biologics impact new targeted immunosuppressive agentsJanus kinase inhibitor JAKi  remains unclear study aimed evaluate risk HBV reactivation among rheumatoid arthritis RA patient treated JAK inhibitors compared receiving TNF inhibitor rituximab conducted retrospective analysis RA patient treated National Taiwan University Hospital 2015 2023 Patients available baseline HBV status HBsAg antiHBc antiHBs HBV DNA received TNF inhibitors rituximab JAKi tofacitinib baricitinib upadacitinib included primary outcome hepatitis flare HBsAgpositive patient HBsAg seroreversion HBsAgnegativeantiHBcpositive patients included 35 HBsAgpositive patient 339 patient resolved HBV infection HBsAgnegativeantiHBcpositive Among resolved HBV infection reactivation risk low TNF inhibitor 09 281000 personyears higher rituximab 32 1511000 personyears JAKi overall 29 1031000 personyears Among individual JAK inhibitors upadacitinib highest incidence 65 4281000 personyears followed baricitinib 47 1921000 personyears tofacitinib 10 271000 personyears Among HBsAgpositive patients 50 JAKi user developed hepatitis flare emphasizing importance vigilant monitoring prophylaxis finding reveal nonnegligible risk HBV reactivation among RA patient receiving JAKi therapy particularly JAK1selective JAKi Larger registry prospective study needed validate findings",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40794751/",
        "source_type": "Global"
    },
    {
        "pmid": "40793974",
        "title": "Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment.",
        "abstract": "Tenofovir alafenamide TAF shown noninferior efficacy tenofovir disoproxil fumarate TDF superior bone renal safety characterise 5year TAF efficacy safety patient East Asian ethnicity pivotal Phase 3 studies Patients randomised 21 receive TAF TDF 3 year doubleblind treatment followed openlabel TAF Patients either continued TAF switched TDF TAF Week 96 TDF → TAF 3 years Week 144 TDF → TAF 2 years treatment Efficacy endpoint virologic biochemical serologic safety assessed Among 591 patient East Asian ethnicity TAF n  401 TDF → TAF 3 years n  84 TDF → TAF 2 years n  106 high rate virologic control achieved 89 94 92 respectively Year 5 missing  failure analysis Year 5 rate alanine aminotransferase normalisation 85 90 78 hepatitis B e antigen loss 36 43 44 similar Following switch TDF TAF change fasting lipid parameter consistent removal known lipidlowering effect TDF However change total cholesterol highdensity lipoprotein ratio marker cardiovascular risk minimal comparable group Year 5 Renal bone parameter improved switching 5 years rate virologic suppression high East Asian patient treated TAF switched TDF TAF TAF TDF well tolerated improved renal bone safety observed patient switching TDF TAF",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40793974/",
        "source_type": "Global"
    },
    {
        "pmid": "40793828",
        "title": "Regulation of Viral Hepatitis by N6-methyladenosine RNA Methylation.",
        "abstract": "Recent study shown presence RNA modification N6methyladenosine msup6supA viral RNAs infection significantly impact outcome viral replication pathogenesis particular various function msup6supA elucidated hepatitis B virus HBV hepatitis C virus HCV hepatitis delta virus HDV viral infection msup6supA methylation directly affect replication virus also regulates diverse cellular RNAs control pathogenesis review aim explore function msup6supA modification infectious process pathogenesis HBV HCV HDV Understanding role msup6supA methylation viral life cycle essential elucidating pathogenesis developing novel therapeutic strategy HBV HCV HDV infections",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40793828/",
        "source_type": "Global"
    },
    {
        "pmid": "40791485",
        "title": "Discovery of Inhibitors Targeting the RNA-Dependent RNA Polymerase of the Zika Virus.",
        "abstract": "Zika virus ZIKV Orthoflavivirus linked several neurological developmental diseases remains significant global health threat treatment vaccine currently available study optimized malachite green colorimetric assay previously used measure RNAdependent RNA polymerase RdRp activity hepatitis C foot andmouth disease viruses applied assay identify inhibitor ZIKV RdRp enzyme essential viral replication Inhibitor screening conducted using 204 compound Natural Product Set IV National Cancer Institute Developmental Therapeutics Program identified two compounds purpurogallin digallic acid inhibitor ZIKV RdRp Future study characterize potency elucidate mechanism action compounds",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40791485/",
        "source_type": "Global"
    },
    {
        "pmid": "40790753",
        "title": "Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D.",
        "abstract": "Viral hepatitis pose considerable risk public health Among five hepatitis viruses hepatitis B C virus particular concern due high rate chronic infection significant global disease burden World Health Organizations Global Health Sector Strategy introduced 2016 seek eradicate viral hepatitis public health issue 2030 aiming 90 decrease new infection 65 drop fatality rates Currently several preventive therapeutic intervention effectively halt progression disease advanced stage Nevertheless forthcoming therapy must prioritize safety effectively manage viral progression timely manner Enhanced understanding molecular immunological mechanism underlying hepatitis viruses infection would facilitate formulation effective treatment strategies review summarizes pathogenesis viruses explores prevention strategy vaccination public health measures discusses current emerging treatments Emphasizing ongoing global effort future directions review highlight critical need sustained international collaboration achieve eradication chronic viral hepatitis",
        "mesh_terms": [
            "Humans",
            "Antiviral Agents",
            "Hepatitis B virus",
            "Hepatitis C",
            "Hepatitis B",
            "Hepatitis D",
            "Hepacivirus",
            "Global Health",
            "Hepatitis Delta Virus"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40790753/",
        "source_type": "Global"
    },
    {
        "pmid": "40790556",
        "title": "Dynamic changes in liver stiffness measurement by 2D shear-wave elastography predict hepatocellular carcinoma in patients with chronic hepatitis B and well-controlled viremia: a retrospective study.",
        "abstract": "Antiviral treatment reduces eliminate risk hepatocellular carcinoma HCC patient chronic hepatitis B CHB Predicting HCC risk population remains challenging study aimed use dynamic change liver stiffness measurement LSM obtained using twodimensional 2D shearwave elastography SWE predict HCC patient noncirrhotic cirrhotic CHB wellcontrolled viremia retrospectively enrolled 303 patient CHB 45 patient cirrhosis wellcontrolled viremia hepatitis B virus DNA  100 IUmL ≥ 6 months antiviral treatment Patients followed every 36 month two twelve reliable LSMs using 2D SWE Clinical laboratory variables single LSM change two LSMs dynamic LSM change analyzed using least absolute shrinkage selection operator multivariable Cox regression analysis identify risk factor HCC Dynamic LSM change classified sustained low LSM all LSMs ≤ 81 kPa unstable LSM LSM ≤ 81 kPa least  81 kPa least once sustained high LSM all LSMs  81 kPa Among 303 patients 27 developed HCC multivariable analysis sustained high LSM dynamic LSM change HR  11624 95 CI 424131861 P  0001 compared sustained low LSM older age HR  1046 95 CI 10091084 P  0013 independently predicted HCC novel model combining age dynamic LSM change achieved Cindex 0845 internal validation demonstrating reliable agreement predicted observed probability HCC development novel model showed better performance noncirrhotic patient Cindex 0860 whereas Cindex 0634 cirrhotic patients Dynamic LSM change predict HCC patient CHB wellcontrolled viremia especially noncirrhotic patients",
        "mesh_terms": [
            "Humans",
            "Carcinoma, Hepatocellular",
            "Elasticity Imaging Techniques",
            "Hepatitis B, Chronic",
            "Liver Neoplasms",
            "Retrospective Studies",
            "Female",
            "Male",
            "Middle Aged",
            "Viremia",
            "Adult",
            "Liver Cirrhosis",
            "Liver",
            "Antiviral Agents",
            "Risk Factors",
            "Predictive Value of Tests",
            "Aged",
            "DNA, Viral",
            "Hepatitis B virus"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40790556/",
        "source_type": "Global"
    },
    {
        "pmid": "40789459",
        "title": "Antihyperlipidaemic activity by flavonoids from the aerial part of Rhinacanthus nasutus.",
        "abstract": "Rhinacanthus nasutus known traditional medicine treatment fungal infections viral hepatitis skin disease Zhuang nationality Guangxi study eleven known flavonoid isolated aerial part R nasutus structure compound determined spectroscopic methods including 1D NMR ESIMS knowledge first instance documenting identification compound 111 plant isolated flavonoid evaluated antihyperlipidemic 16hydroxy2methoxy2″2″dimethylpyrano5″6″34234methylenedioxyphenyl12ethanedione 3 derrubone dimethyl ether 4 robustinmethylether 5 57dimethoxy63 methyl2butenyl 34methylenedioxy isoflavone 6 exhibited certain lipidlowering activity",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40789459/",
        "source_type": "Global"
    },
    {
        "pmid": "40789194",
        "title": "Prevalence and severity of depression in patients with chronic viral hepatitis in Kazakhstan.",
        "abstract": "Depression common issue among patient chronic viral hepatitis Living chronic hepatitis create chronic stress known risk factor developing exacerbating depression stress related concern health effectiveness treatment social implication illness Neuropsychological scale assessment objectively measure severity depression mental health issue patients presence depression studied 233 patient chronic viral hepatitis treated Infectious Disease Hospital Shymkent Regional Hepatology Centre Shymkent period March 2021 January 2022 patient examined using Hamilton Depression Rating Scale HDRS identify presence depression 233 patient chronic viral hepatitis 383 mild depressive disorder 27 patient score indicating moderate depressive disorder 27 patient found major depressive disorder Multivariate analysis showed older age form chronic viral hepatitis higher viral load female gender strongly associated depression Depression common manifestation patient chronic viral hepatitis lead cognitive impairment difficulty concentration memory problems decreased executive function context chronic hepatitis may already affect liver function metabolic processes untreated depression exacerbate cognitive deficits",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40789194/",
        "source_type": "Global"
    },
    {
        "pmid": "40789095",
        "title": "The Principle of Double Effect and Organ Donors with Hepatitis C.",
        "abstract": "AbstractSolid organ transplant save lives demand transplantable organ outpaces supply Traditionally organ patient infected Hepatitis C virus HCV ineligible donation recipient without HCV HCV DR transplants owing concern intentionally transmitting HCV organ recipients New directacting antiviral HCV increased HCV organ opioid epidemic promised solve organ shortage 2017 American Society Transplantation argued HCV DR transplant ethically permissible maximize transplantable organs utilitarian argument suffers flaw inherent utilitarianism could made obsolete resolving organ supplydemand mismatch better argument ethical HCV DR transplant arises principle double effect PDE good effect prolonging life transplantation outweighs evil effect infecting recipient HCV PDE provides ethical grounding HCV DR transplant creates better informed consent discussions",
        "mesh_terms": [
            "Humans",
            "Hepatitis C",
            "Tissue Donors",
            "Tissue and Organ Procurement",
            "Organ Transplantation",
            "Antiviral Agents",
            "Informed Consent",
            "Ethical Theory",
            "Hepacivirus",
            "United States"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40789095/",
        "source_type": "Global"
    },
    {
        "pmid": "40788553",
        "title": "Therapeutic evaluation of bone marrow mesenchymal stem cells for hepatitis virus infection: immunoregulation, anti-inflammatory effects, and clinical potential - a systematic review.",
        "abstract": "One kind stem cell essential regenerative medicine mesenchymal stem cell MSCs common chronic viral infectious disease world viral hepatitis characterized potentially fatal liver inflammation brought hepatitis virus infection liver cells Hepatitis B virus HBV infection spread horizontally via contaminated blood vertically from mother child Hepatitis C Virus HCV main cause chronic liver disease mainly spread sharing needles receiving unsterilized blood transfusions intercourse contaminated blood study employ systematic review design using PRISMA method screening 19 journal based specific inclusion exclusion criteria Exosomes umbilical cord MSCs UCMSCs effectively suppressed interleukin 1β interleukin 6 transforming growth factor β1 vitro liver fibrosis model inhibited LX2 activation reducing extracellular matrix protein COL αSMA bone marrow MSC BMMSC group showed significantly higher 24week survival rate standard medical therapy SMT group MSCs secrete key antiinflammatory cytokine mediating immunomodulatory effect supporting regeneration differentiation potential Pretreating MSCs various stimulus enhances therapeutic efficacy liver transplantation BMMSCs improve liver function reduce infections increase survival due immunomodulatory antiinflammatory properties allogeneic autologous BMMSC UCMSC transplant cause secondary liver cirrhosis related chronic hepatitis B strict monitoring necessary prevent side effect like carcinogenesis viral transmission MSCs also influence angiogenesis tumor cell secreting growth factors Bone Marrow Mesenchymal Stem Cells BMMSCs Umbilical Cord Mesenchymal Stem Cells UCMSCs demonstrate promising therapeutic efficacy viral hepatitis infection various mechanisms including immunomodulation antiinflammatory effects regenerative potential Vigilant monitoring adverse effect necessary ensure safety clinical use",
        "mesh_terms": [
            "Humans",
            "Mesenchymal Stem Cells",
            "Mesenchymal Stem Cell Transplantation",
            "Immunomodulation",
            "Exosomes",
            "Hepatitis, Viral, Human",
            "Liver Cirrhosis",
            "Bone Marrow Cells",
            "Cell Differentiation",
            "Anti-Inflammatory Agents"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40788553/",
        "source_type": "Global"
    },
    {
        "pmid": "40788479",
        "title": "The impact of anti-HBc positivity on clinical outcomes and treatment response in immune thrombocytopenia.",
        "abstract": "Immune thrombocytopenia ITP autoimmune disorder characterized low platelet count due destruction platelet autoantibodies presence hepatitis B core antibody antiHBc marker previous occult hepatitis B virus HBV infection may influence clinical course treatment outcome ITP patients retrospective study investigated impact antiHBc positivity clinical outcome response treatment ITP patients total 116 patient ITP divided 2 groups antiHBc positive n  31 antiHBc negative n  85 Clinical data including platelet count diagnosis followup response corticosteroid treatment remission rate analyzed result indicated antiHBc positive patient significantly lower platelet count diagnosis p  0009 longer hospital stay p  0042 Additionally patient demonstrated lower complete response rate initial corticosteroid treatment 1 month p  0001 6 month p  0021 compared antiHBc negative patients however significant difference overall response durable response rate group 12 months risk relapse higher antiHBc positive patient p  0041 finding suggest antiHBc positivity may associated severe disease course reduced treatment efficacy ITP highlighting importance assessing hepatitis B serological marker managing ITP patients",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40788479/",
        "source_type": "Global"
    },
    {
        "pmid": "40788226",
        "title": "Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data.",
        "abstract": "phase 3 ALLIANCE study bictegraviremtricitabinetenofovir alafenamide BFTAF dolutegravir plus emtricitabinetenofovir disoproxil fumarate DTG  FTDF achieved high rate HIV1 RNA suppression week 96 adult HIV1 hepatitis B virus initiating treatment NCT03547908 study quantify preexisting HIV1 resistance evaluate effect HIV1 virologic suppression describe postbaseline HIV1 resistance week 96 Preexisting HIV1 resistance assessed historical andor screening genotyping HIV1 RNA suppression 50 copy cmL week 96 assessed preexisting resistance category Postbaseline resistance assessed participant HIV1 RNA ≥200 cmL week 96 Primary nucleosidenucleotide reverse transcriptase inhibitor nonnucleoside reverse transcriptase inhibitor protease inhibitor resistance substitution present baseline 4 17 19 79 5 21 241 participants respectively Virologic suppression rate high irrespective preexisting primary resistance substitutions including M184I Six participant 3 per group confirmed HIV1 RNA ≥200 cmL resuppress 50 cmL study drugs none 5 postbaseline resistance data treatmentemergent primary resistance substitutions One participant DTG  FTDF multiple virologic failure documented nonadherence pill count treatmentemergent K70E M184VI subsequently resuppressed people HIV1 hepatitis B virus treated firstline BFTAF DTG  FTDF preexisting HIV1 resistance uncommon affect virologic suppression treatmentemergent HIV1 resistance occurred BFTAF supporting high barrier resistance regimen",
        "mesh_terms": [
            "Adult",
            "Female",
            "Humans",
            "Male",
            "Middle Aged",
            "Adenine",
            "Alanine",
            "Anti-HIV Agents",
            "Dibenzocycloheptenes",
            "Drug Combinations",
            "Drug Resistance, Viral",
            "Drug Therapy, Combination",
            "Emtricitabine",
            "Hepatitis B",
            "Heterocyclic Compounds, 3-Ring",
            "Heterocyclic Compounds, 4 or More Rings",
            "HIV Infections",
            "HIV-1",
            "Oxazines",
            "Piperazines",
            "Pyridones",
            "Tenofovir",
            "Viral Load",
            "Amides"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40788226/",
        "source_type": "Global"
    },
    {
        "pmid": "40788183",
        "title": "Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma.",
        "abstract": "study evaluated safety tolerability preliminary efficacy M1c6v1 oncolytic virus combined immune checkpoint inhibitor ICIs camrelizumab vascular endothelial growth factor receptor 2 VEGFR2 inhibitor apatinib advanced hepatocellular carcinoma HCC singlearm investigatorinitiated openlabel clinical trial enrolled patient advanced HCC NCT04665362 Patients received M1c6v1 1×10⁹ CCID50 intravenously 5 day every 28 days camrelizumab 200 mg intravenously biweekly apatinib 250 mg orally daily Treatment continued 1 year disease progression intolerability withdrawal Primary endpoint safety tolerability secondary endpoint assessed efficacy based tumor response progressionfree survival PFS overall survival OS Thirteen patient enrolled 846 hepatitis B virus HBVrelated HCC 769 presenting tumor 10 cm treatment welltolerated 9215 adverse event AEs grade 1 2 common AEs included influenzalike symptom transient cytopenia viral shedding detected secretion excretion collected subjects 10 patient evaluable efficacy overall response rate ORR 70 710 7 partial response PR according mRECIST median OS PFS 154 89 month respectively combination M1c6v1 camrelizumab apatinib demonstrates acceptable safety profile promising efficacy advanced HCC",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40788183/",
        "source_type": "Global"
    },
    {
        "pmid": "40787894",
        "title": "Author Response: Unpacking the 'Four-Support' Model: Towards Contextual Adaptation in HCV Care Cascade.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40787894/",
        "source_type": "Global"
    },
    {
        "pmid": "40787473",
        "title": "Chronic viral hepatitis B: evaluation of the care of patients monitored at the SMIT in Tivaouane, Sénégal.",
        "abstract": "Chronic hepatitis B livertropic disease caused hepatitis B virus HBV hepatitis B surface antigen persisting beyond 6 months According 2024 report Pasteur Institute prevalence chronic HBV infection Senegal alarming ranking among highest world 10 17 Senegal currently standardized algorithm management chronic hepatitis B Since 2017 European Association Study Liver EASL proposed new classification chronic hepatitis B surveillance scheme objective evaluate management patient viral hepatitis B rural area according EASL criteria Retrospective prospective descriptive study analytical aim March 15 2022 December 7 2024 SMIT Mame Abdou Aziz Sy Dabakh hospital Tivaouane Included patient chronic hepatitis B benefited initial management assessment according criterion EASL Data captured using Kobocollect software encoded analyzed using R software V440 Ethical consideration respected collected 72 patients median age 34 year 2841 female predominance 569 Housewives 347 teacher 167 represented notion familial liver cancer 1667 reported 4167 first degree well second degree discovery HBV carriage made assessment initiated practitioner 639 prenatal assessment 19 blood donation 97 Nine patient 1251 symptomatic hepatitis B eantigen dosage negative 69 patient 9553 median alanine aminotransferase level 2310 IUl 163225 viral load 3795 IUml 371562 Two hepatitis virusHBV coinfections observed Fibrosis F0F1 found 825 cases F2F3 143 cirrhosis 32 Tenofovir disoproxil fumarate treatment initiated 10 patient 139 according 2017 EASL guidelines Ineligible patient 861 placed surveillance rate frequency depended initial phase Among patient lost followup 42 surveillance 6764 four treatment 40 Lack treatment high cost care main reason exclusion followup multivariate analysis factor significantly associated loss followup study highlight challenge managing chronic viral hepatitis B rural areas high cost monitoring lack treatment majority patient contribute loss followup",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40787473/",
        "source_type": "Global"
    },
    {
        "pmid": "40787461",
        "title": "Immunological and clinical overlap between autoimmune gastritis and autoimmune liver diseases: a prospective cohort study.",
        "abstract": "Autoimmune gastritis AIG autoimmune liver disease AILDsincluding autoimmune hepatitis AIH primary biliary cholangitis PBC primary sclerosing cholangitis PSCare chronic organspecific immunemediated disorders condition frequently cooccur autoimmune diseases prevalence clinical overlap immunological association AIG AILDs remain underexplored investigate prevalence AIG patient AILD characterize clinical serological histopathological feature overlap improve early detection guide integrated management strategies conducted prospective study 104 patient confirmed diagnosis AILD participant screened antiparietal cell antibody APCA testing positive underwent upper gastrointestinal endoscopy gastric biopsies Histological assessment based updated Sydney System evaluation mucosal inflammation glandular atrophy intestinal metaplasia APCA positivity observed 221 AILD patients female predominance 783 median age AIG diagnosis APCApositive patient 58 years Among APCApositive individuals histological confirmation AIG achieved 913 high rate intestinal metaplasia 957 variable OLGA stage gastric atrophy Comorbid autoimmune condition common 435 APCApositive patient also presenting autoimmune thyroiditis Notably PBC disproportionately represented APCApositive subgroup 478 compared overall cohort 390 study highlight clinically significant association AIG AILDs particularly patient PBC concurrent autoimmune conditions Given elevated risk gastric mucosal atrophy potential neoplastic transformation targeted screening AIG AILD patientsespecially APCA positivity thyroid autoimmunityshould considered finding underscore importance crossspecialty surveillance open new avenue research shared immunopathogenic mechanisms study found significant number patient autoimmune liver diseases especially primary biliary cholangitis also show sign autoimmune gastritis result support consideration targeted screening gastric involvement selected patient improve early detection clinical management associated complications",
        "mesh_terms": [
            "Humans",
            "Female",
            "Male",
            "Middle Aged",
            "Prospective Studies",
            "Gastritis",
            "Autoimmune Diseases",
            "Aged",
            "Adult",
            "Hepatitis, Autoimmune",
            "Autoantibodies",
            "Cholangitis, Sclerosing",
            "Liver Cirrhosis, Biliary",
            "Parietal Cells, Gastric",
            "Prevalence"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40787461/",
        "source_type": "Global"
    },
    {
        "pmid": "40786815",
        "title": "Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies.",
        "abstract": "contemporary epidemiology hepatocellular carcinoma HCC show shift main etiological risk factor less common highly virulent eg hepatitis C B common weak risk factor eg alcohol metabolic syndrome Therefore seemingly paradoxical state declining overall incidence rate HCCrelated improved prevention treatment viral hepatitis burgeoning number people elevated risk HCC Several geographic region reported increase HCC attributable alcoholic liver disease metabolic dysfunction associated steatotic liver disease MASLD importance risk stratification increasing allow targeted prevention early detection HCC risk factor predispose HCC formation cirrhosis served main risk stratifying factor However scheme showing crack end spectrum one hand risk developing HCC varies widely among patient contemporary advanced fibrosis cirrhosis hand onethird MASLDrelated HCC occurs among patient clear evidence cirrhosis use multidimensional eg clinical epidemiological biochemical predictive algorithm may improve risk stratification efforts shift HCC risk factor also heightened importance limitation current surveillance practice eg reduced performance ultrasound MASLD Therefore exploring advanced imaging methods new biomarkers also existing combination biomarkers augmented clinical factor HCC early detection crucial",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40786815/",
        "source_type": "Global"
    },
    {
        "pmid": "40786326",
        "title": "Prevalence and Predictors of Occupational Exposure to Blood and Body Fluids Among Healthcare Workers in a Tertiary Care Hospital in Eastern India.",
        "abstract": "Background Healthcare worker HCWs increased risk occupational exposure blood body fluid BBFs leading transmission bloodborne infections Despite global data limited information available regarding prevalence predictor exposure Bihar India Methods hospitalbased crosssectional study conducted among 250 HCWs including resident doctors MBBS interns nursing staff paramedical staff India Institute Medical Sciences AIIMS Patna January October 2021 Stratified random sampling used Data collected using pretested semistructured questionnaire Descriptive statistics chisquare test Fishers exact test logistic regression employed analysis Statistical significance set pvalue less 005 Results mean age participant 27 years 52 female 22 reported least one occupational exposure BBFs duty AIIMS Patna 164 experienced exposure past year Needle stick injury 473 common mode exposure Twothirds participant fully vaccinated hepatitis B Following universal precaution significantly reduced odds exposure adjusted odds ratio AOR 019 95 CI 009040 Higher knowledge awareness score also protective AOR 008 95 CI 001058 Conclusion Occupational exposure BBFs remain considerable risk among HCWs Promoting universal precaution practices enhancing knowledge awareness ensuring complete hepatitis B vaccination coverage crucial minimizing risks",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40786326/",
        "source_type": "Global"
    },
    {
        "pmid": "40786261",
        "title": "Fulminant Primary Biliary Cholangitis-Autoimmune Hepatitis (PBC-AIH) Overlap Syndrome in a 27-Year-Old Woman With Childhood-Onset AIH: Steroid-Refractory Decompensation Necessitating Urgent Transplant Evaluation.",
        "abstract": "Autoimmune hepatitis AIH primary biliary cholangitis PBC represent distinct autoimmune liver diseases characteristic clinical serological histological features Rarely patient may exhibit overlap syndrome presenting diagnostic therapeutic challenges describe 27yearold woman longstanding history childhoodonset AIH subsequently developed clinical serologic feature consistent PBC fulfilling Paris criterion AIHPBC overlap syndrome Despite aggressive treatment highdose corticosteroids experienced rapid clinical deterioration developing acute hepatic encephalopathy requiring intensive care unit admission liver biopsy confirmed coexistence interface hepatitis typical AIH florid bile duct lesion characteristic PBC Notably patient steroidrefractory course systemic autoimmune comorbidities including ulcerative colitis pyoderma gangrenosum exhibited atypical earlyonset disease progression Ultimately due severe refractory liver failure required urgent liver transplantation evaluation case highlight aggressive clinical course critical management complexity AIHPBC overlap syndrome emphasizing importance early recognition comprehensive histologic evaluation combined immunosuppressive cholestatic therapies expedited referral transplantation refractory cases",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40786261/",
        "source_type": "Global"
    },
    {
        "pmid": "40785957",
        "title": "Epidemiology of reportable infectious diseases in the Najran Health Cluster.",
        "abstract": "control disease outbreak promote prevention disease monitoring burden infectious illness epidemiology essential Keeping track change disease rate and crucially effectiveness control measure like immunization campaign eradication certain infectious illness depends heavily national surveillance data study analyzed national surveillance data illustrate evolving epidemiology reportable infectious disease Najran Health Cluster 2022 2024 disease incidence rate per 100000 population 95 confidence interval calculated using population census data 2022 2024 year number case described sex nationality age Statistical analysis performed using SPSS Pearsons ChiSquare Fishers exact test assessed association disease incidence population demographics common bacterial disease brucellosis pulmonary tuberculosis salmonellosis 2024 outbreak pertussis cholera incidence rate 52 76100000 respectively common viral disease measles hepatitis B dengue fever chickenpox 2024 marked increase number confirmed hepatitis B cases 100 case 2023 256 2024 common parasitic disease scorpion sting malaria cutaneous leishmaniasis amebic dysentery number reported case malaria almost doubled 45 2023 88 2024 study highlight importance tracing infectious disease data identify outbreak early implement control measures 2024 increase number confirmed case hepatitis B pertussis cholera malaria situation requires urgent investigation",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40785957/",
        "source_type": "Global"
    },
    {
        "pmid": "40785933",
        "title": "Differentiation of dual- and non-dual-phenotype hepatocellular carcinoma based on contrast-enhanced computed tomography and patient characteristics.",
        "abstract": "Dualphenotype hepatocellular carcinoma DPHCC associated higher risk recurrence little known clinicodemographic characteristic imaging features study aimed assess whether contrastenhanced computed tomography CECT patient characteristic facilitate preoperative differentiation DPHCC nonDPHCC Features CECT image clinicodemographic characteristic retrospectively analyzed consecutive series hepatocellular carcinoma HCC patient January 2020 December 2020 Disease confirmed based surgical pathology CECT performed within four week surgery Univariate multivariate logistic regression analysis performed identify independent risk factor DPHCC imaging model based CECT feature combined model based clinicodemographic characteristic CECT feature constructed respectively Delongs test used comparison area curve AUC value two models KaplanMeier survival analysis used assess overall survival OS DPHCC nonDPHCC groups total 29 patient DPHCC 140 nonDPHCC included study DPHCC significantly prevalent among female patient less prevalent among infected hepatitis B virus HBV CECT associated DPHCC rim arterial phase hyperenhancement APHE peripheral washout whereas associated nonDPHCC nonrim APHE nonperipheral washout Multivariate logistic regression identified one independent CECT feature DPHCC rim APHE odds ratio OR 11040 95 confidence interval CI 19863532 imaging model constructed based rim APHEpredicted DPHCC AUC 0562 95 CI 04390684 Multivariate logistic regression identified three independent clinicodemographic characteristic CECT feature DPHCC female sex OR 4519 95 CI 152913357 infection HBV OR 0234 95 CI 00840654 rim APHE OR 15016 95 CI 233596585 combined model constructed based three independent predictor DPHCC AUC 0716 95 CI 06030829 Delongs test showed AUC combined model higher imaging model difference statistically significant Z3207 P005 OS rate patient DPHCC nonDPHCC group 687 772 respectively KaplanMeier survival analysis showed statistical difference OS rate group P0362 combined model established based female sex infection HBV rim APHE CECT facilitate preoperative differentiation DPHCC nonDPHCC DPHCC likely cause death nonDPHCC suggesting active postoperative management patient DPHCC required",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40785933/",
        "source_type": "Global"
    },
    {
        "pmid": "40785902",
        "title": "Donafenib <i>vs.</i> lenvatinib combined with transarterial chemoembolization as initial therapy for unresectable hepatocellular carcinoma: a retrospective real-world study.",
        "abstract": "combination tyrosine kinase inhibitor TKIs transarterial chemoembolization TACE hold promise unresectable hepatocellular carcinoma HCC study aimed directly compare efficacy safety donafenib DonaTACE ivsi lenvatinib LENTACE firstline therapies retrospective study 93 unresectable HCC patient 49 DonaTACE 44 LENTACE 93 hepatitis B virusinfected treated October 2020 May 2023 analyzed Patients received TACE conventional drugeluting beads combined Dona 200 mg twice daily LEN 812 mgday Outcomes included overall survival OS progressionfree survival PFS objective response rate ORR disease control rate DCR adverse event AEs Survival analysis employed KaplanMeier logrank tests Median OS mOS 1400 month DonaTACE ivsi 1900 month LENTACE hazard ratio HR 125 95 confidence interval CI 078199 P0330 Median PFS 737 ivsi 577 month HR 0785 95 CI 046133 P0354 significant differences ORR 5510 ivsi 6136 P0541 DCR 7551 ivsi 8182 P0460 comparable DonaTACE showed significantly lower overall AE rate any grade 8571 ivsi 10000 P0013 grade ≥3 2245 ivsi 4545 P0027 including reduced hypertension 204 ivsi 3636 P0001 diarrhea 612 ivsi 2500 P0011 vomiting 000 ivsi 4091 P0001 DonaTACE LENTACE demonstrated comparable efficacy unresectable HCC DonaTACE exhibited superior safety profile suggesting potential preferable option patient higher comorbidity risks prospective study warranted validate findings",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40785902/",
        "source_type": "Global"
    },
    {
        "pmid": "40785381",
        "title": "Immunoinformatics study of CD40 ligand-targeting vaccine constructs: a novel immunotherapeutic approach.",
        "abstract": "Incorporating CD40 ligand CD40L vaccine strategy shown considerable potential enhancing immune responses study designed formulated CD40Lbased multiepitope vaccine construct using immunoinformatics approaches compared fulllength CD40Lbased vaccine construct study commenced identification screening potential Tcell Bcell epitope derived CD40L protein followed construction multiepitope vaccine selected epitopes analyzed validated physicochemical structural property vaccine constructs Further predicted disulfide bonds performed proteinprotein docking conducted molecular dynamic simulation evaluate constructs Comparative analysis ligandbinding site localization conducted using LigPlot Additionally simulation trajectory analyzed using multiple descriptors including root mean square deviations radius gyration root mean square fluctuations finding indicated CD40L multiepitope vaccine construct possessed favorable physicochemical property validated structural profile Immune simulation study showed stronger affinity multiepitope construct CD40 receptor compared fulllength CD40L construct Overall CD40L multiepitope vaccine construct demonstrated greater potency eliciting effective immune response fulllength CD40L construct result highlight promising approach vaccine design prevention treatment infection cancers",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40785381/",
        "source_type": "Global"
    },
    {
        "pmid": "40785185",
        "title": "Preclinical development and a phase I trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer.",
        "abstract": "Autologous EpCAMtargeted CART cell therapy IMC001 developed advanced gastric cancer GC study evaluated specificity efficacy safety IMC001 preclinical model phase doseescalationexpansion trial patient failed least two line therapy IMC001 specifically recognized EpCAM exhibited potent antitumor activity EpCAMpositive tumor cells xenograft models patientderived organoids August 2021 May 2023 12 advanced GC patient received IMC001 patient experienced grade 3 4 treatmentrelated adverse events mainly lymphopenia related lymphodepletion treatmentrelated deaths Five patient experienced cytokine release syndrome n3 grade 34 two patient experienced immunerelated hepatitis n1 grade 3 middledose group n1 grade 4 highdose group Partial response observed 333 13 lowdose patient 40 25 middledose patients achieving objective response rate 30 disease control rate 70 Median progressionfree survival overall survival 45 84 months respectively One patient underwent conversion surgery week 27 remains alive 315 month postinfusion finding demonstrate acceptable safety profile promising efficacy IMC001 advanced GC supporting clinical development refractory GC patients",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40785185/",
        "source_type": "Global"
    },
    {
        "pmid": "40784973",
        "title": "High risk of hepatic complications in kidney transplantation with chronic hepatitis C virus infection.",
        "abstract": "Data liver issue including liver cirrhosis hepatocellular carcinoma hepatic failure renal transplant patient HCV infection scarce present study conducted largescale populationbased analysis investigate longterm outcome renal recipient HCV infection Propensity score matching ratio 11 applied total 6473renal recipient HCV infection case group enrolled PSM finding showed subject HCV infection kidney transplant significantly higher risk hepatoma cirrhosis hepatic failure overall hepatic disease without HCV infection hepatoma HR 8957 95 CI 532415069 cirrhosis HR 5378 95 CI 43636631 hepatic failure HR 3258 95 CI 25274200 overall hepatic disease HR 4128 95 CI 34284971 present study finding show renal recipient HCV infection significantly associated remarkably high risk hepatic complication postkidney transplantation",
        "mesh_terms": [
            "Humans",
            "Kidney Transplantation",
            "Male",
            "Female",
            "Middle Aged",
            "Hepatitis C, Chronic",
            "Adult",
            "Risk Factors",
            "Liver Cirrhosis",
            "Postoperative Complications",
            "Liver Neoplasms",
            "Carcinoma, Hepatocellular",
            "Hepacivirus"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40784973/",
        "source_type": "Global"
    },
    {
        "pmid": "40784876",
        "title": "Trained human bone marrow mesenchymal stem cells restore tissue immuno-microenvironment in fulminant hepatic failure mice.",
        "abstract": "Trained immunity human bone marrow mesenchymal stem cell hBMSC promising approach liver regeneration study aimed clarify trainedhBMSC ThBMSC restoring tissue immunomicroenvironment fulminant hepatic failure FHF mice hBMSC trained tumor necrosis factorα interferonγ phenotypically characterized vitro FHF mouse model established male Balbc mouse via tail vein injection concanavalin A therapeutic potential ThBMSC evaluated transplantation FHF mice Transcriptomic analysis performed elucidate mechanism liver regeneration posttransplantation ThBMSC ThBMSC characteristic trilineage differentiation potential showed proinflammatory IL1β IL8 p  00001 immunoregulatory gene PDL1 IDO1 p  00001 significantly upregulated compared untrainedhBMSC UThBMSC Timetrajectory analysis revealed downregulation proinflammatory gene IL6 IL8 IL1α upregulation immunomodulatory gene IDO1 ThBMSC upon mimicstimulation characterized distinct transcriptional programs liver function ALT AST inflammatory cytokine IL6 MCP1 p  001 level significantly improved ThBMSCtreated mice survival status ThBMSC group superior UThBMSC group although statistical significance Histological analysis confirmed reduced necrosis fewer infiltrating CD45supsup immune cell ThBMSCtreated mice Significant downregulation immune response TNF  IL17 signaling pathway neutrophil chemotaxis upregulation metabolic pathway observed ThBMSC group associated enhanced liver regeneration proportion antiinflammatory F480supsupCD163supsup macrophage increased liver ThBMSC group ThBMSC exhibited enhanced immunomodulation effectively rescuing liver failure reducing inflammation via restoring immunemicroenvironment finding highlighted potential trained immunity novel strategy treatment liver failure",
        "mesh_terms": [
            "Animals",
            "Liver Failure, Acute",
            "Mesenchymal Stem Cells",
            "Humans",
            "Mice",
            "Male",
            "Mesenchymal Stem Cell Transplantation",
            "Mice, Inbred BALB C",
            "Liver Regeneration",
            "Cell Differentiation",
            "Disease Models, Animal",
            "Cellular Microenvironment",
            "Liver",
            "Bone Marrow Cells"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40784876/",
        "source_type": "Global"
    },
    {
        "pmid": "40784805",
        "title": "[Research progress on the impact of metabolic associated fatty liver disease on viral activity, treatment response, and prognosis in patients with chronic hepatitis B: current status and prospects].",
        "abstract": "Chronic hepatitis B CHB gradually progress lifethreatening disease cirrhosis hepatocellular carcinoma HCC recent years change peoples lifestyles incidence rate metabolic associated fatty liver disease steadily increasing patient combined CHB MAFLD significantly surged However impact MAFLD patient CHB aspect antiviral response clinical outcomes others still controversial article review research progress impact MAFLD regard natural course antiviral treatment response CHB survival rate combination CHB MAFLD provide certain theoretical reference prevention diagnosis treatment disease",
        "mesh_terms": [
            "Humans",
            "Hepatitis B, Chronic",
            "Antiviral Agents",
            "Prognosis",
            "Hepatitis B virus",
            "Fatty Liver",
            "Liver Neoplasms",
            "Non-alcoholic Fatty Liver Disease",
            "Carcinoma, Hepatocellular",
            "Survival Rate"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40784805/",
        "source_type": "Global"
    },
    {
        "pmid": "40784802",
        "title": "[Analysis of liver histological characteristics and clinically related factors in patients with inactive HBsAg carriers].",
        "abstract": "bObjectiveb analyze liver histological characteristic clinically related factor inactive hepatitis B surface antigen HBsAg carrier IHC also explore whether antiviral treatment necessary IHC defined 2022 version hepatitis B prevention treatment guidelines bMethodsb multicenter retrospective cohort study conducted Two hundred thirtyone IHC case underwent liver biopsy histopathological examination nine medical institutions including Beijing Youan Hospital affiliated Capital Medical University January 2018 December 2023 included General informative data clinical serological markers transient elastography TE examination result collected Patients divided positive 148 cases negative group 83 cases according result hepatitis B virus HBV DNA detection difference liver pathological inflammatory activity G liver fibrosis stage S analyzed two group explore correlation liver tissue condition clinically related factors Comparsions normally distributed continwous data skeukd continuous data categorical data group performed using iti tests MannWhitney iUi test i􀱽isup2sup tests respectively bResultsb age 231 IHC case 43 38 51 year old 952 220231 aged ≥30 years male accounted 649 150231 HBsAg HBV DNA level 1319 208 4009 IUmL 940 0 4485 IUmL respectively 359 83231 HBV DNA negative 20 IUmL remarkable proportion G≥2 S≥2 liver injury G≥2 andor S≥2 liver tissue 165 38231 29 67231 359 83231 respectively S≥2 proportion significantly higher HBV DNAnegative group positive group 422 ivsi 216 iPi0001 mainly occurred population cohort 30 year old 449 ivsi 310 iPi004 liver stiffness measurement LSM aspartate transaminase platelet ratio index APRI platelet PLT significantly higher S≥2 group S2 group iPi005 bConclusionb Clinicians comprehensively evaluate degree liver fibrosis IHC based clinical factor age PLT APRI LSM even liver histological result lacking China 2022 version guideline define nearly half IHC histological indication antiviral therapy liver biopsy prompt treatment recommended",
        "mesh_terms": [
            "Humans",
            "Retrospective Studies",
            "Liver",
            "Hepatitis B Surface Antigens",
            "Male",
            "Female",
            "Hepatitis B virus",
            "Hepatitis B",
            "DNA, Viral",
            "Liver Cirrhosis",
            "Adult",
            "Middle Aged",
            "Carrier State",
            "Biopsy",
            "Hepatitis B, Chronic"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40784802/",
        "source_type": "Global"
    },
    {
        "pmid": "40784798",
        "title": "[Clinical characteristics, diagnosis, and treatment strategies for drug-induced autoimmune hepatitis].",
        "abstract": "Druginduced liver injury DILI important adverse drug reaction diverse clinical manifestations Druginduced autoimmunelike hepatitis DIALH special type DILI possessing clinical serological histological feature similar autoimmune hepatitis AIH However significant difference DIALH AIH term treatment plan course disease prognosis therefore differential diagnosis DIALH AIH crucial article summarizes epidemiology pathogenesis clinical characteristics diagnosis differential diagnosis treatment prognosis DIALH analyzes existing problem order provide guidance diagnosis treatment future research direction",
        "mesh_terms": [
            "Humans",
            "Chemical and Drug Induced Liver Injury",
            "Diagnosis, Differential",
            "Hepatitis, Autoimmune",
            "Prognosis"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40784798/",
        "source_type": "Global"
    },
    {
        "pmid": "40784795",
        "title": "[Diagnosis and treatment strategies of autoimmune hepatitis and future challenges].",
        "abstract": "Autoimmune hepatitis AIH kind immunemediated chronic liver disease specific pathogenesis yet fully elucidated recent years International Autoimmune Hepatitis Expert Group revised histology autoantibody evaluation criterion diagnosing AIH clarified definition treatment response current standard treatment regimen still glucocorticoid azathioprine novel biological agent offer new therapeutic option patient refractory AIH article review new progress diagnosis treatment AIH explores current challenge future research directions",
        "mesh_terms": [
            "Humans",
            "Hepatitis, Autoimmune",
            "Azathioprine",
            "Glucocorticoids",
            "Autoantibodies",
            "Immunosuppressive Agents"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40784795/",
        "source_type": "Global"
    },
    {
        "pmid": "40784794",
        "title": "[Advances in clinical diagnosis and treatment of autoimmune liver diseases combined with viral hepatitis].",
        "abstract": "Autoimmune liver disease AILDs group chronic inflammatory liver disease mediated autoimmune disorders viral hepatitis group infectious disease mainly induced hepatotropic viruses resulting liver inflammation necrotic lesions viral infection risk factor AILDs two condition may coexist article provides review diagnosis treatment AILDs combined viral hepatitis recent years",
        "mesh_terms": [
            "Humans",
            "Hepatitis, Autoimmune",
            "Hepatitis, Viral, Human",
            "Autoimmune Diseases"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40784794/",
        "source_type": "Global"
    },
    {
        "pmid": "40784334",
        "title": "Limited Prognostic Impact of Sustained Virologic Response on Atezolizumab plus Bevacizumab Therapy for HCV-related Unresectable Hepatocellular Carcinoma.",
        "abstract": "Sustained virologic response SVR favorable prognostic factor patient hepatocellular carcinoma HCC caused hepatitis C virus HCV treated curatively study aimed evaluate impact SVR atezolizumab plus bevacizumab AtezBev therapy unresectable HCC uHCC caused HCV retrospective analysis 364 uHCC patient treated AtezBev September 2020April 2025 divided SVR n284 nonSVR n80 group performed clinical characteristics prognosis adverse event compared significant difference group age sex platelet count AFP BCLC stage However SVR group showed significantly better ALBI score 250 vs 216 lower AST 33 vs 57 IUL ALT 23 vs 40 IUL level p001 Median progressionfree survival PFS 71 month SVR group 61 month nonSVR group p0443 median overall survival OS 209 month SVR group 189 month nonSVR group significant difference group p0560 Following IPW adjustment factor related OS significant difference regarding PFS p0921 OS p0927 Multivariate analysis identified age ≥75 year poor hepatic function mALBI grade 2b3 independent predictor poor OS SVR status independent factor Changes ALBI ChildPugh score time significantly different groups nonSVR group adverse event common compared SVR group including liver dysfunction 275 vs 130 p0001 edemaascites 125 vs 92 p0015 Although SVR independently associated better survival patient SVR preserved liver function experienced fewer adverse events factor may indirectly support improved tolerability therapeutic option AtezBev therapy HCVrelated uHCC",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40784334/",
        "source_type": "Global"
    },
    {
        "pmid": "40784197",
        "title": "Comparison of diagnostic performances of HDV-RNA quantification assays used in clinical practice: Results from a national quality control multicenter study.",
        "abstract": "reliable quantification hepatitis virus HDV RNA paramount importance monitoring patient antiviral therapy quality control study compare diagnostic performance quantitative HDVRNA assay used clinical practice Two HDVRNA sample panel quantified 30 center RoboGene N  9 laboratories EurobioPlex N  7 RealStar N  4 AltoStar N  1 Bosphore N  3 BosphoreonInGenius N  1 DiaPro N  2 NuclearLaserMedicine N  1 3 inhouse assays Panel B comprised 8 serial dilution WHOHDV standard range 0550 log10 IUml 20 clinical sample range 0560 log10 IUml respectively following parameter determined sensitivity 95  LOD limit detection precision intra interrun CV coefficient variation accuracy difference expectedobserved HDVRNA linearity linear regression analysis 95  LOD varied across assay center underlining heterogeneous sensitivities AltoStar lowest 95  LOD 3 IUml followed RealStar 10 minmax 3316 IUml BosphoreonInGenius 10 IUml RoboGene 31 3316 IUml NuclearLaserMedicine 31 IUml EuroBioplex 100 100316 IUml Moreover 6 assay RoboGene EurobioPlex RealStar AltoStar NuclearLaserMedicine Inhouse showed 05 log10 IUml difference expected observed HDVRNA dilution assay 1 log10 IUml underestimations RealStar BosphoreonInGenius EurobioPlex highest precision mean intrarun CV  20  Interrun CV higher assays CVs  25  RealStar AltoStar NuclearLaserMedicine EurobioPlex Seven assay RoboGeneAltoStarRealStarEurobioPlexNuclearLaserMedicineInhouse showed good linearity Rsup2sup  090 HDVRNA  1000 IUml BosphoreonInGenius AltoStar RealStar Robogene showed Rsup2sup  085 study underline heterogeneous sensitivity inter intraassays could hamper proper HDVRNA quantification particularly low viral loads raise need improve diagnostic performance assay properly identifying virological response antiHDV drugs",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40784197/",
        "source_type": "Global"
    },
    {
        "pmid": "40784196",
        "title": "Heterogeneity of false reactivity profiles of HIV assays while optimizing national HIV testing algorithms: Findings from a multi-country analysis.",
        "abstract": "study highlight importance verifying HIV testing algorithm reduce risk misdiagnoses caused common false reactivity 2020 2023 supported 14 country assess rate false reactivity shared false reactivity across HIV rapid diagnostic test RDTs used HIV testing services study involved 26278 result 22 different RDT products sample size ranging 100 302 result per country number RDT product assessed varied 4 13 per country False reactivity rate ranged 0  332  one country reporting high false reactivity rate 4  one RDT Five country shared false reactivity RDTs remaining eight country shared false reactivity across one six pair RDT products finding used inform national policy 90  country introducing new RDT product HIV testing algorithm based results study concludes rate false reactivity shared false reactivity RDT product vary across countries Therefore conducting verification study crucial updating national HIV testing algorithm ensuring accurate diagnosis also facilitating market entry new HIV testing products",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40784196/",
        "source_type": "Global"
    },
    {
        "pmid": "40783913",
        "title": "Mutation-specific structural changes in BRAF: understanding dimerization and drug binding for targeted therapy.",
        "abstract": "dimerization BRAF CRAF critical regulatory mechanism within MAPKERK signaling cascade disruption mutation BRAF kinase domain contributes tumorigenesis across various cancers wildtype BRAF depends RASmediated dimerization activation oncogenic mutation alter dependency impacting structural conformation ATPdrug binding downstream signaling Despite extensive functional data structural biophysical consequence mutation remain poorly defined Here examine five BRAF mutation oncogenic V600E G469E D594G benign N581S E586K molecular dynamic simulations ATPbinding assessments drug interaction analysis involving Sorafenib U0126 result suggest V600E stabilizes activation loop active monomeric form bypassing dimerization conferring resistance Sorafenib G469E retains dimerization dependence show intermediate activity exhibit moderate drug responsiveness D594G kinaseinactive mutant function scaffold CRAF activation transient ATPinduced stabilization minimal Sorafenib sensitivity Benign variant maintain wildtypelike structural integrity dimer stability inhibitor response Simulations highlight mutationspecific effect key regions including Ploop DFG motif catalytic loop reveal distinct conformational landscape free energy compactness analyses finding provide mechanistic framework linking structure function BRAF mutants supporting mutationguided therapeutic strategy precision oncology",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40783913/",
        "source_type": "Global"
    },
    {
        "pmid": "40782354",
        "title": "Community-Based Micro-Elimination of Hepatitis C Virus in a Defined Rural Cohort: Outcomes From the Nagawa Project.",
        "abstract": "Hepatitis C virus HCV infection remains global public health concern many carrier remaining undiagnosed asymptomatic nature Although Japan previously considered track national HCV elimination 2030 recent global modeling study updated elimination dashboard indicate Japan currently track underscore importance locally coordinated effort detect residual cases Microelimination recently emerged pragmatic scalable approach targeting defined population geographic areas Nagawa Project sought identify HCV positive individual communitywide screening directing viremic case appropriate directacting antiviral DAA therapy present study describes implementation outcome cohortbased HCV microelimination strategy 5027 adult resident Nagawa town Japan aged ≥ 20 year prospectively targeted HCV antibody testing routine health checkups outpatient visits mailed invitation June 2021 March 2024 HCV Antibody positive individual underwent additional HCV core antigen testing confirm viremia total 3121 resident 621 underwent HCV antibody testing Testing rate significantly higher earlystage elderly 6574 years 737 resident adult 2064 years 545 p  0001 latestage elderly ≥ 75 years 667 p  0001 residents Twentyeight individual 0897 HCV antibody positive three case 0096 confirmed viremic Antibody positivity significantly higher latestage elderly resident 191 p  0001 vs adult p  0031 vs earlystage elderly residents Two viremic individual received DAA therapy achieved sustained virological response adjusting age sex propensity score matching significant difference overall survival observed HCV antibody positive negative individuals Nagawa Project illustrates success locally coordinated HCV microelimination approach offer practical framework identifying managing residual HCV infections contributing progress toward Japans alignment World Health Organizations 2030 HCV elimination goals",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40782354/",
        "source_type": "Global"
    },
    {
        "pmid": "40782323",
        "title": "Safety evaluation of deucravacitinib: a real-world analysis based on the FDA adverse event reporting system database.",
        "abstract": "Deucravacitinib novel highly selective tyrosine kinase 2 allosteric inhibitor recently approved treatment moderatetosevere psoriasis adults though postmarketing safety data remain limited purpose study perform postmarketing safety evaluation deucravacitinib based Food Drug Administration Adverse Event Reporting System FAERS database study collected adverse event AE report deucravacitinib primary suspected drug FAERS database third quarter 2022 fourth quarter 2024 Four main method disproportionality analysis including reporting odds ratio proportional reporting ratio Bayesian confidence propagation neural network multiitem gamma Poisson shrinker employed signal detection Potential risk signal deemed significant four algorithm simultaneously met thresholds important medical event IME term list used identify IMEs deucravacitinib Additionally Weibull distribution used evaluate timetoonset TTO characteristics Thirtynine preferred term identified potential risk signals commonly reported AE acne mouth ulceration folliculitis Sixteen AEs potential risk signal mentioned label also identified including urticaria oral pain oropharyngeal pain swelling face lip swelling eye swelling cellulitis ear pain pharyngeal swelling Bells palsy mouth swelling cheilitis mycobacterium tuberculosis complex test positive facial paralysis hepatitis A central nervous system CNS infection Rhabdomyolysis Bells palsy facial paralysis CNS infection identified IMEs associated deucravacitinib study Weibull distribution indicated TTO characteristic deucravacitinibassociated AEs followed early failure type study provides new safety data deucravacitinib realworld settings uncovering previously unrecognized risk identifying several IMEs finding somewhat supplemented safety data deucravacitinib Given limitation FAERS database postmarketing safety surveillance study deucravacitinib remain necessary future",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40782323/",
        "source_type": "Global"
    },
    {
        "pmid": "40782246",
        "title": "Identifying key genes involved in HBV-related hepatocellular carcinoma: diagnose, prognosis, interaction and immune analysis.",
        "abstract": "Hepatitis B virus associated hepatocellular carcinoma HBVHCC serious global health problem study aimed uncover key gene HBVHCC clarity function interaction diagnostic prognostic value impact immune infltration potential drug targeting genes Four gene expression datasets totally containing 117 paired tumor tissue adjacent control tissue selected GEO database used screen differentially expressed gene DEGs Function analysis performed using GO KEGG enrichment STRING cytoscape used analyze proteinprotein interaction PPI screen hub gene Survival analysis receiver operator characteristic ROC curve used explore prognostic diagnostic value key genes Immune infiltration analysis performed CIBERSORT algorithm DrugGene Interaction Database DGIdb used screen potential drug affect hub genes Overall 234 shared DEGs screened four GSE datasets mainly enrichment cell growth regulation epoxygenase P450 pathway cellular response multiple ion xenobiotic metabolic process complement activation Six hub gene HMMR NDC80 CDK1 EZH2 ESR1 FOXM1 screen PPI analysis ESR1 downregulated associated favorable prognosis HBVHCC HMMR NDC80 CDK1 EZH2 upregulated correlation shorter overall survival Furthermore ROC analysis nomogram demonstrated high diagnostic performance NDC80 CDK1 EZH2 Immune infiltration analysis showed significant difference several immune cell type tumor control tissues including cells monocytemacrophage dendritic cells significant correlation hub gene immune infiltration Finally DGIdb analysis showed several approved new drug interaction HMMR CDK1 ESR1 EZH2 Six huggenes closely related HBVHCC development involved multiple biological progress immune infiltration Among them NDC80 CDK1 EZH2 could severed marker good diagnostic prognostic value Notably several approved drug interaction hub gene might potential drug used HBVHCC therapy",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40782246/",
        "source_type": "Global"
    },
    {
        "pmid": "40781975",
        "title": "Trends and disparities in human immunodeficiency virus and chronic liver disease mortality in the United States: A nationwide analysis.",
        "abstract": "ObjectivesWith advance antiretroviral therapy life expectancy individual living human immunodeficiency virus infection significantly improved Consequently nonacquired immunodeficiency syndromerelated conditions particularly chronic liver disease become increasingly prominent cause mortalityMethodsA retrospective analysis conducted using mortality data Centers Disease Control Prevention WideRanging Online Data Epidemiologic Research database spanning 1999 2020 identified death among adult aged 25 year older human immunodeficiency virus infection chronic liver disease listed cause death Data grouped gender age race region Ageadjusted mortality rate calculated per 1 million adult United States Annual percent change computed using Joinpoint regressionResultsFrom 1999 2020 13447 death United States human immunodeficiency virus infection chronic liver disease listed cause death overall ageadjusted mortality rate 249 Males higher ageadjusted mortality rate 385 female 108 NonHispanic Black population higher ageadjusted mortality rate 871 Hispanics 33 nonHispanic white 229ConclusionMortality human immunodeficiency virus infection chronic liver disease listed cause death declined racial disparity persist particularly among nonHispanic Black individuals Addressing disparity require policy improve care access reduce liver diseaserelated risk among people living human immunodeficiency virus infection",
        "mesh_terms": [
            "Humans",
            "Male",
            "Female",
            "United States",
            "HIV Infections",
            "Adult",
            "Middle Aged",
            "Retrospective Studies",
            "Aged",
            "Liver Diseases",
            "Cause of Death",
            "Health Status Disparities",
            "Chronic Disease"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40781975/",
        "source_type": "Global"
    },
    {
        "pmid": "40781938",
        "title": "Five-Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment.",
        "abstract": "Longterm nucleostide analog NUC therapy essential chronic hepatitis B CHB management However data longterm outcomes particularly patient switching tenofovir alafenamide TAF patient chronic kidney disease CKD remain limited study aimed evaluate 5year virological effectiveness renal safety sequential TAF therapy focus preexisting CKD realworld multicenter retrospective study included 414 CHB patient aged ≥ 18 year switched prior NUC TAF followed least 5 years Patients stratified based renal function CKD nonCKD baseline Study endpoint included 5year virological efficacy biochemical fibrosis responses renal function changes Among patients 100 242 CKD time switching TAF 5 years HBV DNA suppression rate increased 850 100 HBV DNA suppression target detected rate rose 740 910 alanine aminotransferase normalization rate AASLD criteria improved 660 790 similar result patient nonCKD Estimated glomerular filtration rate remained stable regardless baseline renal status prior NUC regimen demonstrating longterm renal safety case HBV DNA breakthrough including among previously combination NUCs patient cirrhosis FIB4 index significantly improved time p  0008 Sequential TAF therapy demonstrated robust virological efficacy biochemical fibrosis improvements excellent renal safety 5 years irrespective baseline renal function",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40781938/",
        "source_type": "Global"
    },
    {
        "pmid": "40781716",
        "title": "Targeting NOTCH1-KEAP1 axis retards chronic liver injury and liver cancer progression via regulating stabilization of NRF2.",
        "abstract": "Chronic liver injury key factor disease like hepatocellular carcinoma HCC steatohepatitis NASH viral hepatitis type B C HBV HCV Understanding molecular mechanism crucial effective treatment NOTCH1 signaling pathway though fully understood implicated liver injury may potential therapeutic target Clinical HCC HBV HCV NASH sample additional vitro vivo performance subjected confirm role NOTCH1 downstream target via series biochemical assays molecular analysis approach targeted signaling pathway assay etc RESULTS present study first verified abnormal elevation NOTCH1 hepatocytes patient steatohepatitis HCC HBV HCV mouse models Crucially discovered hepatocytespecific NOTCH1 knockout reduces hepatocellular damage chronic liver inflammation HCC mouse models whereas adenoassociated virus serotype 8 AAV8mediated NOTCH1 overexpression hepatocytes exacerbates liver injuryrelated phenotype onsetting Mechanistically showed NOTCH1 new role controlling ferroptosis oxidative damage hepatocytes interacts Kelchlike ECHassociated protein 1 KEAP1 directly recruited intracellular domain NICD1 Additionally KEAP1 recruited NOTCH1 impeded binding stability KEAP1NFE2 like BZIP transcription factor 2 Nrf2 promote separation KEAP1 Nrf2 thereby reducing stability Nrf2 hindering ubiquitinationrelated proteasome degradation Nrf2 Crucially also discovered NOTCH1s ANK domain essential NICD1KEAP1 contact signaling activation inability NOTCH1 ANK domain mutant ΔANK connect KEAP1 increase expression emphasizes importance ANK domain KEAP1NRF2 signaling reversing downregulation KEAP1 overexpression NRF2 ANK function linked ferroptosis ROS buildup ANK domain targeting may slow course HCC liver damage Targeting NOTCH1KEAP1NRF2 axis possible chronic hepatic injury therapy supported findings identify NOTCH1KEAP1 NRF2 suppressor accelerates progression liver injury",
        "mesh_terms": [
            "Humans",
            "Animals",
            "NF-E2-Related Factor 2",
            "Receptor, Notch1",
            "Liver Neoplasms",
            "Kelch-Like ECH-Associated Protein 1",
            "Mice",
            "Disease Progression",
            "Carcinoma, Hepatocellular",
            "Signal Transduction",
            "Male",
            "Disease Models, Animal"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40781716/",
        "source_type": "Global"
    },
    {
        "pmid": "40781577",
        "title": "Description of Multicopy Recombinant Hepatitis B Surface Antigen: From Expression to Immune Analysis.",
        "abstract": "Hepatitis B virus HBV remains significant global health challenge Although antiviral treatment improved vaccine containing Hepatitis B surface antigen HBsAg still effective prevention method Since 1998 HBV vaccine part Turkiyes mandatory childhood vaccination program vaccine currently imported study primarily aim optimize recombinant HBsAg production Pichia pastoris evaluate immunological comparability commercial HBV vaccine thereby assessing potential locally produced vaccine candidate achieve this eightcopy tandem construct HBsAg gene created pPICZαA plasmid vitro multimerization production process recombinant HBsAg optimized presence HBsAg supernatant following induction confirmed antigen purified using various physical biochemical methods highest yield recombinant HBsAg achieved eightcopy construct following induction 1 methanol harvesting 120 h identified productive time point antigenic property produced HBsAg compared commercially available vaccine Engerix B™ Immunological testing using serum antiHBsAg positive individual immunized animal demonstrated recombinant rHBsAg exhibited similar antigenic characteristic commercial vaccine finding study indicate recombinant HBsAg exhibit immunological property comparable imported vaccine suggest may potential candidate future vaccine development",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40781577/",
        "source_type": "Global"
    },
    {
        "pmid": "40780329",
        "title": "Mapping novel linear B-cell epitopes target Hepatitis C virus envelope proteins E1 and E2 by monoclonal antibodies for increasing the sensitive detection sites.",
        "abstract": "Since protective vaccine Hepatitis C timely diagnosis treatment early stage viral infection crucial prevent control hepatitis C virus HCV causing chronic infection E1 E2 protein HCV produce neutralizing antibody often used screen potential epitopes study human embryonic kidney 293 HEK293F cell used generate highly active HCV E1 E2 proteins used antigen producing mouse monoclonal antibody mAbs Novel B cell epitope E1 E2 disclosed using monoclonal antibody first time Based epitopes three multiepitope MEP antigen designed prepared including nonstructural protein novel identified B cell epitope E1 E2 HCV 1b 2a 3a 6a subtypes Double antigen sandwich enzyme immunoassay established based MEPs detect HCV serum antibodies showing potential diagnostic application study suggests Bcell epitope E1 E2 could contribute development diagnostic reagents provides important reference value theoretical support optimization diagnostic reagent HCV",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40780329/",
        "source_type": "Global"
    },
    {
        "pmid": "40780235",
        "title": "Recompensation in decompensated cirrhosis.",
        "abstract": "Recompensation decompensated cirrhosis defined Baveno consensus control cure main underlying cause resolution clinical manifestations including ascites hepatic encephalopathy without use prophylactic medications without variceal bleeding 12 months restoration hepatic function Cure recompensation usually associated regression liver fibrosis Recompensation occur hepatitis C virus eradicated hepatitis B virus infection without hepatitis coinfection suppressed following persistent alcohol abstinence patient alcoholassociated cirrhosis Although cirrhosis related metabolic dysfunctionassociated steatotic liver disease improve following lifestyle pharmacotherapyassisted weight loss autoimmune liver disease respond immunosuppression unclear true recompensation achieved patients Recompensation cirrhosis could achievable clinical target offsetting cost management advanced liver disease decreasing need liver transplantation Consequently public health policy pursue programme promote alcohol cessation eliminate viral hepatitis address obesity",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40780235/",
        "source_type": "Global"
    },
    {
        "pmid": "40779594",
        "title": "Modeling the effects of treatment adherence challenges on the transmission dynamics of hepatitis C virus.",
        "abstract": "Infectious disease modeling crucial predicting disease progression time help guide decision maker public health policy Hepatitis C virus HCV prevalence still increasing Zimbabwe lowmiddleincome country LMIC despite availability effective treatments reason increase well understood study employed mathematical model explain impact poor treatment adherence HCV transmission dynamic Zimbabwe computed basic reproduction number Formula see text vital metric disease spread Equilibrium state model determined stability investigated study demonstrated adherence level exceeding 52 cause reproduction number drop 1 curtailing spread HCV model indicates variation resusceptibility minimally impact outcomes suggesting resusceptibility often excluded analyses model unraveled synergistic impact simultaneously enhancing recovery rate acutely infected individual treatment adherence reducing Formula see text study underline pressing need stronger health interventions including patient education financial assistance rigorous monitoring improve treatment adherence intervention paramount curbing HCV proliferation particularly LMICs like Zimbabwe serve template similar setting globally",
        "mesh_terms": [
            "Humans",
            "Zimbabwe",
            "Hepatitis C",
            "Hepacivirus",
            "Models, Theoretical",
            "Treatment Adherence and Compliance",
            "Basic Reproduction Number",
            "Antiviral Agents"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40779594/",
        "source_type": "Global"
    },
    {
        "pmid": "40779493",
        "title": "Persistent immunological repercussions of late antiretroviral initiation in children living with HIV.",
        "abstract": "aimed evaluate age antiretroviral treatment ART initiation modified immune parameter vaccine response Brazilian cohort child perinatally acquired HIV longterm treatment Crosssectional study including child  18 years ART ≥ 6 months HIV viral load 50 copiesmL Data abstracted medical chart blood collected serology PBMC isolation Antibody titer hepatitis B rubella mumps measles measured cell marker senescence CD57 anergy CD28 apoptosis CD95 activation CD38 CCR5 HLADR exhaustion PD1 analyzed flow cytometry Children categorized 4 groups ART initiation 6 months ≥6 month 1 year ≥ 1 year 5 years ≥5 years 55 participant median age 12 83159 year median time ART 9 50132 year included Median age ART initiation 18 0636 years Compared starting ART later child initiated ART earlier  1 year age especially  6 months higher CD4 counts CD4 nadir CD4CD8 ratio Earlier ART associated CD4 CD8 profile lower frequency activation senescence exhaustion markers higher antibody titer mumps measles rubella Activation senescence exhaustion marker correlated poorer vaccine response Children started ART later life presented worse immune outcome even longterm ART",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40779493/",
        "source_type": "Global"
    },
    {
        "pmid": "40779238",
        "title": "High sensitivity detection of Hepatitis B virus RNA based on 3D-DNA nanomachine and protein nanopore sensing.",
        "abstract": "Serum Hepatitis B virus HBV RNA serf noninvasive biomarker monitoring chronic hepatitis B guiding treatment decisions However current diagnostic test relying Reverse Transcription Quantitative Polymerase Chain Reaction RTqPCR require centralized facility tedious operational steps currently standardized HBV RNA detection method Herein describe rapid amplificationfree detection HBV RNA clinical serum sample via nanopore sensing method method involves design DNA nanomachine capable translation target HBV RNA large amount 7nt singlestrand DNA ssDNA signal reporter produce blockage feature passing alphahemolysin αHL nanopore target quantified identifying frequency blockage occurrence demonstrate unique nanopore sensing feature distinguishes Signal Report SR DNA interfering nucleic acid clinical serum sample also ensures high assay sensitivity limitofdetection LOD 125 fM clinical potential method validated testing serum sample 26 HBVinfectedpatients 7 healthyparticipants compared RTqPCR method showed one false result achieving accuracy rate 970 Additionally testing result 18 case treatment period demonstrated methods conclusion continued treatment drug discontinuation highly consistent clinical diagnoses accuracy rate 100 Therefore method developed study expands clinical application 3D DNA nanomachine nanopore sensing technology clinical detection",
        "mesh_terms": [
            "Nanopores",
            "Humans",
            "Hepatitis B virus",
            "Biosensing Techniques",
            "RNA, Viral",
            "Hemolysin Proteins",
            "Limit of Detection",
            "DNA, Single-Stranded"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40779238/",
        "source_type": "Global"
    },
    {
        "pmid": "40778988",
        "title": "HCV serology: an unfinished agenda.",
        "abstract": "50 year elapsed since clinical definition nonA nonB hepatitis 36 year since unveiling hepatitis C virus HCV availability specific serological assays advance serological diagnosis HCV infection occurred Testing antiHCV still based detection reactivity towards structural Core region HCV appears dominant throughout different phase infection plus antibody towards antigen expressed several nonstructural regions Unlike testing viral diseases antibody towards envelope region detectable first line assay employed screening diagnosis scarcely represented supplementary assay employed confirm reactivity screening assays Clinical laboratory often confronting issue sample give discrepant result among assay confirmed supplemental testing Results obtained sample usually labelled indeterminate often considered false positive  though true reference define antiHCV positivity still lacking diagnostic answer deprived clinical significance affect patient management counselling advance though recent availability assay detecting HCV core antigen considered surrogate HCV RNA lesser sensitivity bearing operational economic advantage diagnosis population screening lately assay combining HCV antigen antiHCV detection paper summarizes history HCV serology provides insight limitation potential developments",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40778988/",
        "source_type": "Global"
    },
    {
        "pmid": "40778981",
        "title": "Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients.",
        "abstract": "Blockade PD1PDL1 pathway part standard treatment advanced urothelial cancer reliable predictive biomarkers identified Here analyze Multiplexed Quantitative Immunofluorescence pretreatment tumor microenvironment TME urothelial cancer sample patient treated atezolizumab identify correlation treatment efficacy RealWorldEvidence RWE study assessed Multiplexed Quantitative Immunofluorescence expression CD8 PD1 TIM3 LAG3 Tcells different compartment TME tumor stroma whole tissue pretreatment tissue microarrays studied association expression marker clinical efficacy One hundrednine patient received atezolizumab showing overall response rate 238 Safety comparable previous study atezolizumab Pretreatment tumor sample available 45 patients CD8 Tcell density significantly increased tumor compartment stromal compartment patient experiencing complete partial responses compared patient presenting stable disease progression Similar result observed coexpression CD8PD1 CD8TIM3 CD8PD1TIM3LAG3 finding support relevance density spatial distribution CD8 Tcells coreceptors clinical efficacy singleagent PDL1 blockade patient advanced urothelial cancer RWE study valuable tool identifying predictive biomarkers",
        "mesh_terms": [
            "Humans",
            "Hepatitis A Virus Cellular Receptor 2",
            "Lymphocyte Activation Gene 3 Protein",
            "CD8-Positive T-Lymphocytes",
            "Antibodies, Monoclonal, Humanized",
            "Programmed Cell Death 1 Receptor",
            "Male",
            "Female",
            "Biomarkers, Tumor",
            "Aged",
            "Middle Aged",
            "Antigens, CD",
            "Tumor Microenvironment",
            "Aged, 80 and over",
            "Urinary Bladder Neoplasms",
            "Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40778981/",
        "source_type": "Global"
    },
    {
        "pmid": "40778958",
        "title": "Mechanism of METTL14 regulates HBV-HCC malignant progression by mediating m6A modification of FOXP3 and thus transcriptional activation of ALDOB.",
        "abstract": "Hepatocellular carcinoma HCC severe form liver malignancy characterized high incidence mortality rates complex etiology significant variability prognosis Forkhead box P3 FOXP3 essential transcription factor play pivotal role tumorigenesis progression prognosis study aim explore function underlying mechanism FOXP3 malignant progression HCC expression level FOXP3 predicted using TNMplot database KaplanMeier Plotter Survival Analysis KaplanMeier Plotter website utilized analyze correlation gene expression prognosis Gene expression level determined reverse transcription quantitative realtime polymerase chain reaction RTqPCR western blot viability proliferation apoptosis invasion capacity cell detected 345dimethylthiazol2yl25diphenyltetrazolium bromide MTT assay 5ethynyl2deoxyuridine EdU staining flow cytometry transwell assay respectively qPCR assay used detect replication hepatitis B virus HBV enzymelinked immunosorbent assay ELISA utilized detect hepatitis B surface antigen HBsAg glucose consumption lactate production cell measured special kits presence m6A modification FOXP3 jointly predicted using RNA Modification Base RMbase sequencebased RNA adenosine methylation site predictor SRAMP databases Relevant prediction conducted using Gene Expression Profiling Interactive Analysis GEPIA database Encyclopedia RNA Interactomes ENCORI database Cancer Genome Atlas TCGA database explore expression correlation genes N6methyladenosine m6A methylation modification level FOXP3 determined using methylated RNA immunoprecipitation MeRIP assay RNA immunoprecipitation RIP used detect interaction methyltransferaselike 14 METTL14 insulinlike growth factor 2 mRNAbinding protein 1 IGF2BP1 FOXP3 cell treated actinomycin Act D mRNA stability measured RTqPCR dual luciferase reporter assay chromatin immunoprecipitation ChIP used detect interaction FOXP3 aldolase B ALDOB Mouse xenograft assay used vivo validation Gene expression HCC tumor tissue measured immunohistochemistry IHC assay FOXP3 lowly expressed HBVrelated HCC associated poor prognosis patients Overexpression FOXP3 inhibited proliferation metastasis glycolysis HBVrelated HCC cells METTL14 stabilized FOXP3 mRNA m6AIGF2BP1dependent manner METTL14 inhibited malignant behavior HBVrelated HCC cell targeting FOXP3 transcription factor FOXP3 triggered activation transcription ALDOB thereby inhibiting malignant behavior HBVrelated HCC cells METTL14 inhibited tumor growth vivo activating FOXP3 expression METTL14 regulates malignant progression HBVHCC mediating m6A modification FOXP3 IGF2BP1dependent manner thereby activating ALDOB transcription provides new insight targeted therapy HCC",
        "mesh_terms": [
            "Humans",
            "Carcinoma, Hepatocellular",
            "Liver Neoplasms",
            "Forkhead Transcription Factors",
            "Methyltransferases",
            "Adenosine",
            "Disease Progression",
            "Hepatitis B virus",
            "Gene Expression Regulation, Neoplastic",
            "Cell Proliferation",
            "Transcriptional Activation",
            "Cell Line, Tumor",
            "Apoptosis",
            "Prognosis"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40778958/",
        "source_type": "Global"
    },
    {
        "pmid": "40778883",
        "title": "Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab.",
        "abstract": "Combination CTLA4 ipilimumab PD1 nivolumab checkpoint inhibition dualICI improves survival patient advanced melanoma However many patient also experience immunerelated adverse event irAE require systemic treatment corticosteroids Corticosteroids dampen antitumoral response may impair survival Here investigated association irAE overall survival well exposure corticosteroid second line immunosuppressant dual ICItreated patient advanced melanoma ini  205 Patients irAE ini  113 superior OS compared patient irAE ini  92 survival benefit persisted adjusting immortal time bias Regarding specific irAE patient colitis hepatitis rheumatic irAE hypophysitis skinrelated irAE improved OS adjusting negative baseline factors survival benefit persisted hypophysitis ipi  003 hepatitis ipi  004 adjusting immortal time bias whereas rheumatic ipi  005 skinrelated irAE ipi  006 borderline significant Hepatitis colitis required higher dos corticosteroid longer time often secondline immunosuppression compared irAE conclusion irAE associated superior OS patient advanced melanoma treated dual ICI Hepatitis hypophysitis strongly associated better survival outcomes Studies investigating mechanism underlying hepatitis hypophysitis may identify important response mechanisms",
        "mesh_terms": [
            "Humans",
            "Melanoma",
            "Ipilimumab",
            "Nivolumab",
            "Male",
            "Female",
            "Middle Aged",
            "Aged",
            "Hypophysitis",
            "Hepatitis",
            "Antineoplastic Combined Chemotherapy Protocols",
            "Adult",
            "Immune Checkpoint Inhibitors",
            "Aged, 80 and over",
            "Skin Neoplasms"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40778883/",
        "source_type": "Global"
    },
    {
        "pmid": "40778743",
        "title": "Anticoronavirus Activity of Uridine Glycoconjugates Containing a 1,2,3-Triazole Moiety.",
        "abstract": "Coronaviruses spread rapidly new host specie cause severe respiratory enteric disease vertebrates including humans date seven coronaviruses identified humans severe acute respiratory syndrome coronavirus 2 SARSCoV2 notorious due substantial social economic impact Although antiSARSCoV2 vaccine available infection remain widespread highlighting ongoing need antiviral treatments Here report synthesis evaluation activity uridine glycoconjugates designed glycosyltransferase donortype inhibitor incorporating 123triazole moiety compound tested two model coronaviruses murine hepatitis virus strain A59 MHV human coronavirus strain NL63 HCoVNL63 Four synthesized compound demonstrated strong antiviral activity viruses efficacy confirmed SARSCoV2 result suggest compound interfere coronavirus infectivity replication process Thus novel compound may prove effective broadspectrum antiviral inhibitors",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40778743/",
        "source_type": "Global"
    },
    {
        "pmid": "40777746",
        "title": "A potent GalNAc-siRNA drug, RBD1016, leads to sustained HBsAg reduction and seroconversion in mouse models of HBV infection.",
        "abstract": "Potent small interfering RNA siRNA drug could achieve hepatitis B surface antigen HBsAg seroconversion functional cure currently lacking purpose study evaluate therapeutic potential RBD1016 novel GalNAcconjugated siRNA drug targeting transcript hepatitis B virus HBV animal models RBD1016 designed target X gene HBV HBx showed strong activity HBV DNA HBsAg multiple HBV genotype nucleosideresistant viral strain iin vitroi studies single repeated administration RBD1016 two different HBV animal models robust reduction serum HBsAg HBV DNA maximum reduction 37 log demonstrated durable antiHBV effect RBD1016 could still observed day 169 Importantly repeated single administration RBD1016 caused ide novoi production hepatitis B surface antibody HBsAb ie seroconversion animals important hallmark immune response induction Furthermore combination RBD1016 entecavir ETV demonstrated enhanced effect serum HBV DNA inhibition strong durable antiHBV effect RBD1016 alone combination nucleoside analogue NAs indicates significant therapeutic potential chronic hepatitis B CHB patients",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40777746/",
        "source_type": "Global"
    },
    {
        "pmid": "40776613",
        "title": "Serum copper and ceruloplasmin levels as biomarkers reflecting liver fibrosis in children with autoimmune hepatitis.",
        "abstract": "Clinical biochemical histological immunological indicator frequently used diagnose autoimmune hepatitis AIH chronic inflammatory liver disease affecting children Wilson disease resembles AIH mainly evaluated using serum ceruloplasmin copper levels However change biomarkers also observed AIH raising question whether could useful evaluating child AIH selecting treatment plan estimating longterm prognosis patient AIH assessing liver fibrosis stage crucial also crucial identify noninvasive indicator liver fibrosis ceruloplasmin suggested biomarker several liver diseases Therefore study aimed investigate potential significance serum ceruloplasmin copper level identifying liver fibrosis child AIH One hundred child AIH treated Menoufia Universitys National Liver Institute Pediatric Hepatology Gastroenterology Nutrition Department enrolled duration study 5 year February 2020 February 2025 patients histopathological radiographic laboratory clinical data collected used revised score diagnose AIH Beckman Coulter AU480 chemistry analyzer used measure serum copper enzymelinked immunosorbent assay used measure serum ceruloplasmin Serum ceruloplasmin level considerably lower patient advanced fibrosis F34 without advanced fibrosis F02 P0001 However patient extensive fibrosis serum copper level considerably elevated P0001 Compared serum copper level area curve 0939 95 confidence interval CI 08870991 P0001 cutoff 247 mgdL 908 sensitivity 669 specificity ceruloplasmin level area curve 0945 95 CI 0889100 P0001 suggesting could useful tool detection advanced liver fibrosis children estimate longterm prognosis patient AIH crucial assess liver fibrosis stage crucial identify noninvasive indicator liver fibrosis ceruloplasmin suggested biomarker Therefore serum copper ceruloplasmin level may provide important information identification advanced liver fibrosis child AIH",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40776613/",
        "source_type": "Global"
    },
    {
        "pmid": "40776050",
        "title": "A Novel Privacy-Preserving Approach to Enable Remote Data Access and Analytics at Federally Qualified Health Centers: Stop-HCC-HCV Program in South Texas.",
        "abstract": "STOPHCCHCV program screen treat hepatitis C vaccinate hepatitis B prevent hepatocellular carcinoma HCC implementing novel approach includes novel cloudbased privacypreserving platform TripleBlind overcome electronic health record EHR native reporting limitation without removing data four Federally Qualified Health Centers FQHC South Texas USA program serf primarily lowincome medically underserved Latino population HCC occurs higher rate nationally first two FQHCs approach yielded improved accuracy showing 28 308 patients respectively screened previously reported quarterly reporting time decreased many hour multiple day four minutes",
        "mesh_terms": [
            "Texas",
            "Humans",
            "Electronic Health Records",
            "Hepatitis C",
            "Liver Neoplasms",
            "Carcinoma, Hepatocellular",
            "Confidentiality",
            "Hepatitis B"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40776050/",
        "source_type": "Global"
    },
    {
        "pmid": "40775743",
        "title": "Optimizing hepatitis B vaccination in chronic kidney disease: a comprehensive scoping review of strategies across CKD stages, dialysis, and transplant populations.",
        "abstract": "scoping review aim comprehensively map critically analyze existing evidence regarding optimal HBV vaccination strategiesincluding vaccine types schedules immunogenicity duration protection factor influencing seroresponses safetyprimarily adult predialysis dialysisdependent chronic kidney disease CKD populations Patients CKD increased risk hepatitis B virus HBV infection due immune dysfunction frequent blood exposure invasive procedures including hemodialysis Although HBV vaccination crucial CKD patient due high transmission efficacy HBV enhanced regimen adjuvant often required CKDinduced immune dysfunction scoping review followed Joanna Briggs Institute guideline PRISMAScR checklist searching PubMed EMBASE SCOPUS Englishlanguage study August 2024 demonstrated 329 unique records 17 study included Accordingly 4 time either doubledose simple recombinant vaccine EngerixB 40 mcg adjuvanted vaccine eg Fendrixsup®sup HeplisavBsup®sup 20 mcg demonstrated higher seroprotection rate standard conventional schedule 3 time EngerixB 20 mcg Vaccination predialysis stage eGFR  15 mLmin173 msup2sup yielded higher shortterm seroprotection SPR 63100 12 month last dose dialysis patient SPR 50893 12 month last dose antibody titer prominent adjuvant vaccine nonadjuvant one conclusion higher dos vaccination required adult patient CKD however data transplant recipient pediatric patient limited Largescale highquality randomized controlled trial longterm immunity monitoring needed",
        "mesh_terms": [
            "Humans",
            "Hepatitis B",
            "Hepatitis B Vaccines",
            "Immunization Schedule",
            "Kidney Transplantation",
            "Renal Dialysis",
            "Renal Insufficiency, Chronic",
            "Vaccination"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40775743/",
        "source_type": "Global"
    },
    {
        "pmid": "40775738",
        "title": "Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate AKI after cardiac surgery by facilitating miR-21-5p targeting TEAD1.",
        "abstract": "Acute kidney injury AKI common complication cardiac surgery Human umbilical cord mesenchymal stem cell hUCMSCderived exosomes affect tissue damage repair miR215p reduces apoptosis inflammation However miR215ps role cardiac surgery remains unclear Kidney injury molecule KIM1 neutrophil gelatinaseassociated lipid carrier protein NGAL serum creatinine blood urea nitrogen BUN level tested enzymelinked immunosorbent assay hUCMSCs exosomes identified iviai Oil Red staining kit alkaline phosphatase staining kit flow cytometry transmission electron microscopy Western blot immunofluorescence Cell viability apoptosis detected cell counting kit 8 flow cytometry Interleukin1β interleukin6 tumor necrosis factoralpha level tested ELISA kits Relativity miR215p TEA domain family member 1 TEAD1 verified dualluciferase reporter gene assay western blot TEAD1 BUN creatinine level iin vivoi tested iviai immunohistochemistry automatic biochemistry analyzer KIM1 NGAL serum creatinine BUN level increased miR215p expression inhibited AKI cardiac surgery AKI cardiac surgery hUCMSCsExos inhibited apoptosis pyroptosis promoted viability iviai miR215p regulation hUCMSCsExos retarded AKI cardiac surgery progression facilitating miR215p targeting TEAD1 hUCMSCsExos promoted miR215p inhibited TEAD1 expression iin vivoi miR215p knockdown facilitated TEAD1 expression iin vivoi Results exactly iin vivoi iin vitroi AKI models hUCMSCsExos protect AKI enhancing miR215pTEAD1 binding iin vivoi iin vitroi",
        "mesh_terms": [
            "Exosomes",
            "Humans",
            "Acute Kidney Injury",
            "MicroRNAs",
            "Mesenchymal Stem Cells",
            "Animals",
            "Transcription Factors",
            "TEA Domain Transcription Factors",
            "Cardiac Surgical Procedures",
            "Male",
            "DNA-Binding Proteins",
            "Umbilical Cord",
            "Apoptosis",
            "Hepatitis A Virus Cellular Receptor 1",
            "Mice",
            "Disease Models, Animal",
            "Nuclear Proteins"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40775738/",
        "source_type": "Global"
    },
    {
        "pmid": "40775604",
        "title": "Identification of novel pathogenic mutations in <i>ATP6V0A4</i> associated with distal renal tubular acidosis and analysis of wild-type expression in glomerular disease.",
        "abstract": "Distal renal tubular acidosis dRTA rare renal disorder caused genetic mutation secondary factors untreated result significant electrolyte imbalance progressive chronic kidney disease CKD study investigated key gene involved renal tubular acidbase regulation iSLC4A1i iATP6V1B1i iATP6V0A4i whole exome sequencing WES clinical cohort Notably patient iATP6V0A4i mutation diagnosed younger age mean 05 years exhibited severe renal impairment including reduced estimated glomerular filtration rate eGFR indicating heightened susceptibility kidney damage identified novel iATP6V0A4i mutation c2219C  T c1971G  C c2293c2296del AGCG confirmed pathogenicity using bioinformatics iin vitroi experiments demonstrated c1971G  C mutation disrupted mRNA splicing causing exon 5 skipping introducing premature termination codon c2293c2296del AGCG introduced premature termination codon c2219C  impaired protein expression intracellular pH regulation ATPase activity Additionally ATP6V0A4 expression decrease diabetes progression contributing tubular dysfunction development diabetic kidney disease DKD finding underscore crucial role ATP6V0A4 maintaining renal acidbase balance influence CKD progression importance genetic analysis early diagnosis personalized management dRTA",
        "mesh_terms": [
            "Humans",
            "Acidosis, Renal Tubular",
            "Vacuolar Proton-Translocating ATPases",
            "Male",
            "Female",
            "Exome Sequencing",
            "Mutation",
            "Glomerular Filtration Rate",
            "Infant",
            "Child, Preschool",
            "Child",
            "Anion Exchange Protein 1, Erythrocyte",
            "Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40775604/",
        "source_type": "Global"
    },
    {
        "pmid": "40775219",
        "title": "Integrative multi-omics reveals a regulatory and exhausted T-cell landscape in CLL and identifies galectin-9 as an immunotherapy target.",
        "abstract": "Tcell exhaustion contributes immunotherapy failure chronic lymphocytic leukemia CLL Here analyze cell CLL patients blood bone marrow lymph nodes well CLL mouse model using singlecell RNA sequencing mass cytometry tissue imaging cell CLL lymph node show distinct profiles accumulation regulatory cell CD8supsup cell various exhaustion states including precursor TsubPEXsub terminally exhausted TsubEXsub cells Integration Tcell receptor sequencing data use predicTCR classifier suggest enrichment CLLreactive cell lymph nodes Interactome study reveal potential immunotherapy targets notably galectin9 TIM3 ligand Inhibiting galectin9 mouse reduces disease progression TIM3supsup cells Galectin9 expression also correlate worse survival CLL cancers suggesting role immune evasion potential therapeutic target",
        "mesh_terms": [
            "Galectins",
            "Leukemia, Lymphocytic, Chronic, B-Cell",
            "Humans",
            "Animals",
            "Mice",
            "Hepatitis A Virus Cellular Receptor 2",
            "Immunotherapy",
            "T-Lymphocytes, Regulatory",
            "Lymph Nodes",
            "CD8-Positive T-Lymphocytes",
            "Female",
            "Male",
            "Disease Models, Animal",
            "Multiomics"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40775219/",
        "source_type": "Global"
    }
]